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Stacey M. Crane 
Participant Experiences in Phase I Pediatric Oncology Clinical Trials 
Phase I clinical trials (P1Ts) are the first step in testing new medical therapies in 
humans, and are essential for developing new and innovative therapies for children with 
cancer. P1Ts are ethically controversial as they are not intended to directly benefit 
participants, but are particularly controversial for children with cancer who are only able 
to participate when there is no known curative therapy for their cancer. Benefits of 
pediatric oncology P1T participation may include improved quality of life (QOL) and 
hope. Risks may include fostering unrealistic hope, burdening children with additional 
medical procedures and toxicities, and limiting the opportunity for palliation.  
The goal of this dissertation was to investigate the P1T participation experience 
for children with cancer and their parents by: (1) assessing what is currently known 
about the participation experience, (2) exploring ways to understand and assess 
treatment burden and QOL during participation, and (3) interviewing parents about the 
experience of having a child participate in a P1T. Following a review of the literature, 
two studies were conducted: a longitudinal pilot study of 13 parent and child dyads who 
enrolled in a pediatric oncology early phase clinical trial at the recruiting institution, and 
a phenomenological study of 11 parents of children with cancer who participated in 
pediatric oncology P1Ts. 
Key findings included a dearth of research on the experiences of children and 
parents in pediatric oncology P1Ts. Instead, existing research has focused on consent 
processes. The longitudinal pilot study provided some insight into experiences of 
children and parents during trial participation, including that there may be time points 
when parents’ and children’s perceptions of the child’s quality of life substantively 
differ. Interviews with parents confirmed some of the anticipated benefits and risks of 
participation in P1Ts, and highlighted parents’ sense of running out of time to find an 
effective treatment and needing to use time they have with their child well. Specific 
challenges in conducting this research were participant attrition due to disease 
progression and the need for multi-site research to obtain an adequate sample. 
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1.1 INTRODUCTION 
 This chapter introduces the dissertation topic of participant experiences in 
pediatric oncology phase I clinical trials (P1Ts). The chapter includes: a discussion of the 
significance of the topic, a review of the aims of this dissertation and its content, and an 
outline of the dissertation research study methods.  
1.2 SIGNIFICANCE 
 P1Ts are the first step in testing new medical therapies in humans, and are 
essential for developing new and innovative therapies for children with cancer.1,2 The 
goals of these trials are not to determine if the drugs are effective, but rather to: (1) 
determine the maximum-tolerated dose of the drug; (2) identify any drug-related 
toxicities, and (3) describe the absorption, metabolism, and excretion of the drug in 
humans.1,2  
 Although research related to experiences of communication and decision-making 
during pediatric oncology P1T consent processes has been conducted, missing is 
knowledge of parent and child experiences during trial participation. Research on the 
experiences of adult patients in P1Ts demonstrates that while P1T participation provides 
hope and a sense of purpose, there are significant physical, emotional, and practical 
burdens.3-12 Although some insight may be obtained from adult experiences, due to 
children’s reliance on their parents as providers, caregivers, teachers, moral compasses, 
disciplinarians, and proxy decision-makers, adult experiences are not directly 
generalizable to the pediatric population.3-12  
 Ethicists and clinicians suggest that pediatric oncology P1Ts burden children with 
additional medical procedures and toxicities, and may influence subsequent grief, and 
bereavement processes in parents and children.13-16 However, research has not been 
performed on the benefits, burdens, or impact of P1T participation for children or their 
families. The first step of the dissertation was to conduct a background integrative 
review using the guiding question: What is known about how P1T participation can 
impact the well-being (either positively or negatively) of children with cancer and their 
 2 
families? Studies identified explored experiences almost solely during the P1T consent 
process (see Chapter 2 for a full report of the findings).17-27 Although the consent 
process is essential to the P1T experience, it is only one small piece of the experience 
which extends from the first discussion of the P1T, through obtaining consent, 
administration of therapy, and ending with the off-study transition.4,5,7,11,28 This 
dissertation is the first step towards understanding the experience of pediatric oncology 
P1T participation. 
1.2.a Importance of the Pediatric Oncology P1T Experience 
 P1Ts are necessary for identifying new treatments that will continue to improve 
outcomes for children with cancer. Cancer remains the leading cause of death due to 
disease in children under 14 years of age.29,30 The five-year survival rates for several 
pediatric cancers have improved to more than 90%.29-32 However, children with acute 
myeloid leukemia (67%), medulloblastoma (70%), hepatic (74%) and bone (73%) tumors, 
and rhabdomyosarcoma (64%) still have low overall five-year survival rates.29-32  
 Ethically, P1Ts are challenging to conduct due to competing interests. Pediatric 
oncology P1Ts are focused on improving clinical outcomes for future patients rather 
than directly benefiting the children participating in the trials.33-35 The costs of running 
P1Ts are high, and the mean enrollment is 28 to 37 patients per pediatric oncology 
P1T.1,34,36 Each child participating in a P1T can impact whether or not the investigational 
therapy will continue to be developed for the population. From a participants’ 
perspective, there are burdens associated with P1T participation, including that children 
participating in P1Ts undergo research-only procedures that would not otherwise be 
performed.33 By providing insights into participant experiences in P1Ts, this dissertation 
provides a foundation for balancing the well-being of children with cancer and their 
parents who participate in a P1T, with the high stakes of the P1Ts. 
 As the children enrolled in a P1T have a shortened life expectancy, the decision 
of children and their parents to participate in a P1T can be conceptualized as an end-of-
life choice. The cancers of the large majority of children participating in P1Ts will not 
improve. The percentage of cancers that responded partially or completely to pediatric 
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oncology P1T therapies is between 3.8% and 9.6%.1,2,37-40 The median survival time of 
pediatric patients with relapsed cancer after enrollment in a P1T was between 3.6 and 
6.4 months.2,39,40 The overall death rate of children participating in P1Ts ranged from 7% 
to 21% during the trial; however, progressive disease accounted for most of these 
deaths.37,38 Patient outcomes in P1Ts are evaluated by length of survival, immediate 
tumor response to therapy, and toxicities. Although the quality of life and/or well-being 
of children and their parents are assessed in some phase III pediatric oncology clinical 
trials, these are not currently assessed in P1Ts. This dissertation will provide an initial 
understanding of how participating in a P1T can impact the end-of-life experience and 
well-being of children with cancer and their parents. 
1.2.b Potential Future Implications  
 This dissertation will inform current practice and future intervention research 
targeted to enhance parent and child P1T experiences during their participation in a 
P1T. Intervention research with adult P1T participants is underway to improve palliative 
and supportive care provided during trial participation and when being transitioned off 
the trial.41-43 Similarly, potential pediatric P1T interventions could include addressing the 
unique needs of parents and children that arise from trial participation; integrating 
supportive and palliative care within the trials; enhancing the on-trial procedure; and 
facilitating the transition off the P1T at trial conclusion. More specifically, this could 
involve an educational intervention for clinical trial nurses regarding families’ 
experiences, a care coordination intervention which would enable nurses who work 
with families directly to address burdens, or a decision-making intervention to ensure 
that families who elect to pursue a P1T are well-informed as to what to expect during 
their experience in the trial. 
 The ethical challenge of P1Ts is to balance the need for this research with the well-
being of participants. The Declaration of Helsinki requires that “the interests of the 
[research] subject must prevail over the interests of science and society.”44 In order to 
uphold ethical principles of autonomy in relation to informed consent, and non-
maleficence and beneficence in relation to benefits and burden, it is important to 
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describe, understand, and optimize the experience and effects of the P1T on pediatric 
participants and their families.33,45 Such knowledge can inform the design and 
management of P1Ts by providing an appreciation of the P1T experience from the 
perspective of parent participants. By identifying issues in the P1T experience directly 
from parents using their own words, the findings of this study will provide compelling 
evidence for securing additional funding and developing future interventions.  
1.3 AIMS OF THE DISSERTATION 
 The central goal of this dissertation was to develop an understanding of 
participant experiences in pediatric oncology P1Ts. To achieve this goal, the following 
three chapters describe the P1T experience of participating children with cancer and 
their parents through an integrative review and two research studies. 
 Chapter 2 is a comprehensive state of the science integrative review. The 
primary purpose was to synthesize and appraise the evidence of how P1T participation 
can impact the well-being (either positively or negatively) of children with cancer and 
their families. The secondary purposes were to identify gaps in our understanding of the 
impact of pediatric oncology P1T participation, and to determine how those gaps can 
empirically be addressed. 
 Chapter 3 presents the results of the descriptive quantitative pilot study. The 
purposes were to assess the feasibility of having children with cancer and their parents 
complete measures of treatment burden and quality of life concurrent with 
participation in an early phase clinical trial, and to generate preliminary results from 
those measures. 
 Chapter 4 reports the results of the phenomenological study. The purpose was 
to identify the fundamental commonalities and meaning of the experience of P1T 
participation from the perspective of parents of children with cancer who participated in 
a P1T. 
 Chapter 5 synthesizes the findings from the three previous chapters, discusses 
strengths and limitations of the dissertation, and provides recommendations for future 
research and pediatric oncology P1T design and management.  
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1.4 DISSERTATION RESEARCH STUDIES 
 This section presents summary information about the methods of the two 
dissertation research studies. 
1.4.a Descriptive Quantitative Pilot Study 
 The purposes of the descriptive, longitudinal pilot study were to assess the 
feasibility and preliminary results of having children with cancer and their parents 
complete measures of treatment burden and quality of life concurrent with 
participation in an early phase clinical trial. A prospective, longitudinal design was used 
to ensure participant experiences were captured throughout trial participation. 
Treatment burden was assessed using an adapted version of the Collection of Indirect 
and Non-medical direct costs (COIN) form found in the literature.46 Quality of life was 
assessed with PedsQLTM modules, as these modules are extensively used in children 
with cancer and are validated.47-53 
1.4.a.1 Rigor of Research. 
  Rigor was assured by setting measurable standards for evaluating feasibility prior 
to commencing data analysis. These standards were set based on an ad hoc literature 
review of standards used in pilot studies and on study team members’ expertise with 
the population.  
1.4.a.2 Participant Safety Plan. 
 This study was approved by the Cincinnati Children’s Hospital Medical Center 
Institutional Review Board. Potential risks associated with study participation were 
minimal and included only psychological distress when completing study measures and 
potential loss of confidentiality. Significant efforts were taken to maintain participants’ 
anonymity. Since participants were closely monitored in the associated early phase 
clinical trial, additional participant safety monitoring was not instituted for this study.  
1.4.b Phenomenological Study 
 The purpose of the phenomenological study was to identify the fundamental 
commonalities and meaning of the experience of P1T participation from the perspective 
of parents of children with cancer. The specific aim was to develop a rich, in-depth, 
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phenomenological description of parents’ lived experiences of having a child with cancer 
participate in a P1T. Empirical phenomenology with an adapted version of Colaizzi’s 
method was used to answer the specific aim and research question.54 
Phenomenological research is used to describe the essence (i.e. the fundamental 
commonalities and meaning without which a phenomenon would not be what it is) of 
the lived experiences of people in similar life situations.55-58 In addition, child and family 
demographics and the clinical trial record were used to describe the sample, understand 
details specific to the P1T in which the child was enrolled, inform the parents’ 
description of their experiences, and provide context for interpreting experiences.  
 Empirical phenomenology was chosen because: (1) Parents of children who 
participated in P1Ts are likely to have experiences that are rich in meaning and not 
previously elucidated. (2) Narratives of personal experiences are an important first data 
source for capturing the experience, perceived meaning of the experience, and the 
experience’s resultant impact. (3) Empirical phenomenology has been an important first 
step in programs of research that ultimately focused on developing interventions to 
improve patient quality of life outcomes. (4) The systematically derived products of 
empirical phenomenology, both the exhaustive description and the essential structure 
of the experience, will be rich sources of information for further research.  
1.4.b.1 Trustworthiness of Research. 
 Although there is no consensus on how to achieve rigor in qualitative research, it 
is generally accepted that qualitative studies must be conducted in ways that enhance 
the trustworthiness of the findings.59-63 In this study, trustworthiness was enhanced by 
strategies reflecting Lincoln and Guba’s four components of rigor in qualitative research: 
credibility, transferability, dependability and confirmability.59,64  
 Credibility, the truth value of the findings,55,68 was achieved by: (1) adopting a 
phenomenological attitude when interviewing participants and analyzing data, (2) 
conducting bi-weekly meetings for discussion, consensus, guidance, and debriefings, 
and (3) using data from the Demographic Form and the Form for Extraction of Data from 
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Clinical Trial Record to inform the parents’ description of their experiences and provide 
context for interpreting experiences.59,60  
 Transferability, the generalizability of the findings,55,68 is inherently achieved by 
well-conducted empirical phenomenological studies, with adequate sampling.59,65 The 
essence of the lived experience of a phenomenon, which is the finding of a well-
conducted empirical phenomenological study, is intrinsically generalizable when it 
captures the fundamental commonalities and meaning - regardless of context - without 
which the phenomenon would not be what it is.65 The clinical applicability of the 
findings is an important consideration in the generalizability of health research. In this 
study, clinical applicability was evaluated via clinician validation of findings. After data 
analysis was complete, feedback was obtained on the study findings from two 
experienced phase I clinicians (one physician and one nurse) from different participating 
phase I centers.  
 Dependability, the consistency and repeatability of findings,55,68 was achieved by: 
(1) manually verifying the transcribed interview with the audio recording prior to 
starting data analysis, (2) ensuring adherence to empirical phenomenology and in 
particular to Colaizzi’s method of data analysis, (3) reviewing the transcribed interviews 
and analysis to ensure that formulated meanings reflect the participants’ interview data, 
(4) using NVivo™ functionality as an audit trail, and (5) maintaining a reflexive research 
diary of decision-making and theme emergence.59,60,66  
 Confirmability, the consideration of whether the findings can be 
corroborated,55,68 was achieved through: (1) adopting a phenomenological attitude 
when interviewing participants and analyzing data, (2) using written reflections on prior 
personal and theoretical knowledge to identify lapses in bracketing, (3) using NVivo™ 
functionality as an audit trail, (4) maintaining a reflexive research diary of decision-
making and theme emergence, and (5) using data from the Demographic Form and the 
Form for Extraction of Data from Clinical Trial Record to inform the parents’ description 
of their experiences and provide context for interpreting experiences.59,60,66 
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 Colaizzi’s method includes a final step of participant validation of research 
results.54 Participant validation is contentious, however, because the results cannot be 
appreciated without a phenomenological attitude and a disciplinary perspective.60,61,65 
Based on these concerns, participant validation was not done on this study’s results. In 
lieu of this step, clinician validation of results was conducted. 
1.4.b.2 Participant Safety Plan. 
 This study was approved by the Indiana University Institutional Review Board. 
Potential risks associated with study participation were minimal. Risks included 
psychological distress due to the sensitive nature of the topic and potential loss of 
confidentiality. Participants were notified of these risks during the informed consent 
process. All possible efforts were undertaken to de-identify and secure the data 
collected. If any concerns related to participant distress arose during study procedures, 
participants were reminded that participation was voluntary and they could refuse to 
answer any questions, end the interview, or withdraw from the study without fear of 
repercussions. Psychological distress was assessed during the interview and the follow-
up call through participant comments and by the assessment of study burdens and 
benefits (i.e. completion of the Modified Pessin et al. Instrument).67 In particular, 
participants who responded that they were burdened to any extent by participation in 
the phenomenological study were asked if it would be helpful to speak to a psychosocial 
professional.67 If emotional or psychological distress that could require professional 
support was identified, there was a clear procedure for intervention and follow-up.  
 In addition, records of recruitment refusals and feedback from participants were 
maintained throughout the study. On a bi-weekly basis the following were reviewed: 
participant responses to recruitment attempts in terms of number of refusals, methods 
of contact, and reasons for refusal; and any negative feedback from participants. If any 
concerning trends were found, the Institutional Review Board was to be notified and 
adjustments made to recruitment strategies and / or study procedures.  
 Based on prior work with bereaved parents, it was anticipated that negative 
psychological reactions by participants would be uncommon and generally very mild in 
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severity.68 There are no documented instances of research with bereaved parents, in 
general, that resulted in distress requiring professional help or resulting in lasting 
harm.68,69 In contrast, bereaved parents frequently describe research participation as 
positive and personally beneficial, and afterwards do not regret participating.68,70,71 
Bereaved parents have provided the following recommendations for researchers.68,70,71 
(1) The first recruitment approach be in written form. (2) The parent decides where, 
when, and how long to meet. (3) Opportunities are provided for the parent to share 
memories of their child. (4) The researcher uses empathic statements and takes care of 
the parent throughout the research. (5) The parent controls the pace and direction of 
interviews. (6) The parent has an opportunity to speak with researchers following the 
research. (7) The parent is offered an opportunity to learn study results. This study 
followed all of these recommendations. 
1.5 CONCLUSION 
 The cancers of the large majority of children participating in P1Ts will not improve. 
To uphold ethical principles of autonomy in relation to informed consent, and non-
maleficence and beneficence in relation to benefits and burden, the experience and 
effects of P1T participation needs to be understood.  This dissertation investigated the 
P1T experience for participating children with cancer and their parents by: (1) evaluating 
the evidence of how P1T participation can impact the well-being (either positively or 
negatively) of participating children and their families, (2) considering how treatment 
burden and quality of life impact of P1T participation might be assessed, and (3) asking 
parents whose child with cancer participated in a P1T to reflect on and share their 
experiences from throughout the P1T. This dissertation was the first step towards 
understanding the experience of pediatric oncology P1T participation. It can inform 
current practice and the design and management of P1Ts, as well as future intervention 
research targeted to enhance parent and child P1T experiences during their participation 
in a P1T.  
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 This chapter presents the results of an integrative review of the literature related 
to experiences and well-being of participants in pediatric oncology phase I clinical trials.    
2.1 INTRODUCTION 
Cancer remains the leading cause of death due to disease in children under 14 
years of age.31 Although five year survival rates for pediatric cancers have improved 
overall to 81%, for some pediatric cancers the five year survival rate is only 60%.31 New 
therapies are needed to continue to improve outcomes for children with cancer. Phase I 
clinical trials (P1Ts) are the first step in testing new medical therapies in humans, and 
are essential to the development of new and innovative therapies for children with 
cancer.1,2  
Although the need for P1Ts is generally accepted, these trials are ethically 
controversial.14,72-81 The goals of P1Ts are to: determine the maximum-tolerated dose of 
the therapy, describe the action of the therapy in humans, and reveal side effects.1,2 
P1Ts are not intended to provide direct benefit to participants. Instead researchers 
conduct P1Ts to determine how innovative therapies may safely be given. The 
Declaration of Helsinki requires that “the interests of the [research] subject must prevail 
over the interests of science and society”.44 The ethical challenge of P1Ts is to assure the 
well-being of participants within the context of P1Ts.  
Ethical concerns regarding P1Ts are greater in children with cancer as they are 
only eligible to participate in P1Ts when there is no known curative therapy for their 
cancer. Furthermore, children must rely on their parents as proxy decision-
makers.14,76,77,80 Enrolling a child in a P1T provides the child access to a novel 
investigational cancer therapy.82-84 Parents enroll their children in P1Ts primarily based 
on hope of a cure for their child from the novel therapy.17,18,25,74 However, the median 
life expectancy of children after enrollment in pediatric oncology P1Ts is 3.6 - 6.4 
months.2,39,40 Consequently, children enrolled in P1Ts are spending part of their 
remaining lives being treated in a trial that is not intended to provide direct benefit. 
Ethicists and clinicians propose that the potential benefits of pediatric oncology P1T 
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participation may include improved QOL and hope, although the risks include fostering 
unrealistic hope, burdening children with additional medical procedures and toxicities, 
and limiting the opportunity for palliation.13-16,77,85-87 To avoid inadvertent suffering in 
children with cancer near end-of-life and ensure potential P1T participants are well-
informed, a full understanding of how participating in a P1T impacts participants’ well-
being is needed.  
The primary purpose of this integrative review was to synthesize and appraise 
the evidence of how P1T participation positively or negatively impacts the well-being of 
children with cancer and their families. The secondary purposes were to identify gaps in 
our understanding of the impact of pediatric oncology P1T participation, and to 
determine ways existing gaps can be empirically addressed.  
2.2 THE RESILIENCE FRAMEWORK 
Review findings were synthesized using the Resilience in Individuals and Families 
Affected by Cancer Framework (Resilience Framework), the organizing framework for 
nursing research conducted through the Children’s Oncology Group (COG).88,89 This 
framework is used to facilitate an understanding of how children and families sustain or 
regain well-being after a pediatric cancer diagnosis, and guide interventions that can 
promote child and family well-being (see Figure 2.1).88-91 For children and their families 
participating in P1Ts, the Resilience Framework can provide an organizing structure for 
understanding how experiences during the P1T impact the overall well-being of children 
and their families.  
The Resilience Framework includes two risk factors (illness-related distress and 
defensive coping); four protective factors (family environment, social integration, 
courageous coping, and derived meaning), and one outcome factor (well-being).88,89 See 
Table 2.1 for definitions of factors. The risk factors are negatively associated with well-
being, and the protective factors are positively associated with well-being. The well-
being outcome factor includes positive health outcomes such as global QOL, resilience, a 
sense of confidence and mastery, and self-transcendence.88 Per the Resilience 
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Framework, courageous and defensive coping are not mutually exclusive; some coping 
strategies encompass elements of both factors.88 
To ensure that burdens associated with P1T participation were captured, for this 
review treatment burden was an additional indicator of the illness-related distress risk 
factor. Treatment burden refers to the workload associated with a treatment for a 
patient and their family, including the physical, financial, time, psychosocial, and 
procedural demands that a treatment places on a patient and their family.92-95  
2.3 LITERATURE SEARCH 
This integrative review was conducted using the Whittemore and Knafl 
method.96 Two literature searches were performed in December 2016 in PubMed and 
CINAHL Complete (EBSCO) databases, as summarized in Figure 2.2. The first search used 
the key words (1) ‘cancer’ or ‘oncology’; (2) ‘child’ or ‘pediatric’; and, (3) ‘phase 1’, 
‘phase I’, ‘clinical trials, phase 1 (as topic)’, therapies, investigational’, ‘early phase’ or 
‘early trials’. In total, 2,386 articles were identified. For the purposes of this review, 
children included individuals less than 18 years of age. Articles that were expert 
opinions and/or theoretical discussions, non-English, published prior to 1985, lacking an 
abstract, or not relevant to the purposes of the review were excluded. An extensive 
date range was included due to the anticipated paucity of articles and the desire to 
capture historical trends in the P1T experience. Articles concentrating solely on clinical 
trial procedures (e.g. the quality of the P1T consent process) were excluded. The 
reference lists of the included articles were examined using the criteria above, resulting 
in a total of 20 remaining articles.  
The second search focused on adults, given the paucity of articles identified for 
pediatric P1T participant experiences or well-being. Key words were as above, excluding 
the key words ‘child’ or ‘pediatric’. Since a total of 17,197 mainly irrelevant articles were 
identified, the following key words were used to refine the adult literature search: 
‘participation’, ‘qualitative research’, ‘psychosocial factors’, ‘burden’ or ‘supportive’. In 
total, 3,237 articles were identified and screened per above. In addition, because 
informed consent procedures are fundamentally different with adult and pediatric 
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participants, articles that solely considered participant experiences during P1T consent 
processes were excluded. After screening and reviewing the reference lists of included 
articles, 31 additional empirical articles were identified that described the experience or 
well-being of adults during their participation in oncology P1Ts.  
2.4 DATA EVALUATION 
Per the Whittemore and Knafl method, all articles were evaluated based on 
relevance to the review purposes and on theoretical or empirical rigor.96 Scores were 
assigned as either ‘High’, ‘Medium’, or ‘Low’ separately for both relevance and rigor (see 
Table 2.2 and Table 2.3).96 The primary researcher completed assessments of all articles 
in the sample. The dissertation chairthen independently performed a confirmatory 
assessment of 10 randomly selected articles (five pediatric and five adult). Articles were 
not excluded based on their data evaluation ratings, however, the ratings were 
considered during analysis when determining the level of available supporting 
evidence.96 Table 2.4 summarizes article evaluation results. 
2.5 FINDINGS 
Of the 20 pediatric articles (listed in Table 2.2), 11 were empirical research 
studies, one was a case report, and eight were meta-analyses of results from multiple 
P1Ts. Considering just the 11 empirical studies, one analyzed end-of-life care provided 
to P1T participants, one considered nurses’ perceptions of P1Ts, and the remaining nine 
examined experiences during P1T decision-making. Minimal empirical evidence was 
found regarding the experiences or well-being of children with cancer or their families 
during their P1T participation, beyond the process of consenting to a P1T. All 31 adult-
focused articles (listed in Table 2.3) were empirical articles exploring adult patient and 
family experiences in a P1T.  
2.5.a Risk Factor: Illness-Related Distress  
For children with cancer and their parents considering participation in a P1T, 
there was some evidence that overall well-being was associated with being able to 
perform usual physical activities, and not experiencing side effects from cancer or its 
treatments.17 Performance scores are a measure of general well-being and ability to 
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complete activities of daily living.97,98 At enrollment, children participating in a P1T had 
high performance scores overall, despite being heavily pretreated for their cancer.2 This 
was similar to adult participants and anticipated as P1Ts have performance status 
eligibility requirements.12,99-101 No significant changes in performance or overall QOL 
scores were found in adult participants who completed one course of P1T therapy, 
although Rouanne et al. found that physical health of adult participants significantly 
decreased during one course of P1T therapy.6,12,101,102  
In terms of distress due to symptoms of disease, adult P1T participants had 
similar or higher levels of symptom burden than non-participants.100,103 In particular, 
George et al.104 found that adult P1T participants experienced poor sleep quality, which 
was connected to increased symptom burden and disturbances in temperament. 
However, there was some limited evidence that being in a P1T may have positively 
influenced adults’ experience of their symptoms by providing hope for therapeutic 
benefit.6,9 Interestingly, in one study by Rouanne et al.12 the level of severe depression 
in adult P1T participants (2%) was strikingly lower than in both the general cancer 
population (10 to 25%) and the general healthy population (5%). There was good 
evidence for incorporating palliative care and / or hospice simultaneously with P1T 
participation for adults and children, to enhance supportive care and symptom 
management and to decrease psychological distress.41,83,103,105-108 No other symptom 
distress data was available for pediatric P1T participants.  
In terms of outcomes of P1T participation, the pediatric meta-analyses 
established that for most children with cancer participating in a P1T, their cancer did not 
improve. The combined partial and complete response rate for children enrolled in P1Ts 
was between 3.8 –9.6%, with reports of 17-24.5% prolonged stabilization of disease (i.e. 
more than three or four months).1,2,37-40 Although the median overall survival time of 
children with relapsed cancer after enrollment in a P1T was between 3.6 and 6.4 
months, Morgenstern et al.40 reported 16% of children survived longer than 12 months 
and Kim3 reported 5% survived longer than 36 months.2,39,40 The median time in a P1T 
was 1.3 – 1.8 months or 1 cycle.2,39,40 Overall, 13-24% of children with cancer 
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experienced a dose-limiting toxicity, 46.7% experienced a grade 3 or 4 toxicity, 7.6% 
were hospitalized due to toxicities, and 0-2.4% of children died due to toxicities 
experienced during a P1T.1,2,37-40 Death rates of children participating in P1Ts ranged 
overall from 7-21%, however progressive disease accounted for most of the deaths 
occurring during P1Ts.37,38 Despite being more heavily pretreated, pediatric patients had 
a similar or greater medication tolerance than adult patients enrolled on matched 
P1Ts.36,109  
Although empirical research had not yet been conducted on pediatric 
participants’ experiences during P1Ts, there was some evidence that logistics and 
potential impact on QOL contributed to parents’ and children’s decisions whether to 
participate in a P1T.18,22-24 For adults, P1T treatment burdens had a significant impact on 
their overall QOL.3,110 These burdens included frequent hospital visits, additional 
medical procedures and tests, toxicities related to the novel therapy, logistical problems 
such as transportation and parking, and financial cost.3,4,110,111 These burdens were 
manageable and became routine for some participants, yet others continuously 
struggled with them and feared they would become more than they could handle.4 
There was a strong level of evidence that before entering the P1T, adult participants 
were either unaware of or underestimated the practical burdens of being in the trial.3,4 
After enrolling in the P1T, these burdens became more significant. Taking part in a P1T 
was compared to having a job in that there was a strict schedule to follow and specific 
tasks to be performed.3,4,11,110,111 Overall, adults participating in a P1T experienced a 
sense of life being on hold during the P1T, wherein it was difficult to plan for activities as 
their lives revolved around the trial and its requirements.4,11,28,111  
The role of illness-related uncertainty (which includes both complexity and 
ambiguity) was not well explored in the P1T experience of children or adults.88,90 For 
adults, there may be more uncertainty experienced during P1T participation than during 
standard treatments, due to the investigational nature of the novel therapy.4,11 Parents 
considering having their child participate in a P1T spoke of a high degree of uncertainty 
related to unknowns of the P1T and the extra testing needed to verify P1T eligibility.17 
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However, there was some evidence that for adult participants, the specific requirements 
involved with the P1T may have reduced uncertainty by providing a set plan to 
follow.10,43,110,111 In addition, although there are many unknowns regarding the P1T 
therapy and its potential impact on humans, the information that was available from 
pre-clinical and early testing helped P1T participants cope with the uncertainty.43,110,111  
2.5.b Risk Factor: Defensive Coping  
There was good support that adult P1T participants and their families employed 
evasive coping strategies. Adult P1T participants who avoided transitioning to end-of-life 
care demonstrated the strongest evidence of evasive coping.7,41,111 Experts similarly 
hypothesized that participation in a pediatric oncology P1T exacerbates the reluctance 
of families and healthcare providers to address end-of-life issues in children with cancer, 
yet there was no difference in end-of-life care provided to children in P1Ts at a large 
medical center with an active palliative care program.13,15,26 There was also some 
evidence that adult P1T participants were at risk for using evasive coping strategies by 
over-relying on healthcare providers and becoming passive recipients of care.5 This 
over-reliance was demonstrated by 80% of adult P1T participants who wanted the 
healthcare provider to tell them what they should do during trial recruitment.5  
2.5.c Protective Factor: Courageous Coping  
Overall, there was a high level of evidence that participating in a P1T was 
generally a positive experience that supported courageous coping and optimism in 
adults. This was due to participants’ perception of receiving further treatment, trying 
something new, having the support of expert medical care, engaging with the 
healthcare team, contributing to cancer research, and / or having a purpose in their 
lives.4,8,10,11,111-114 The stories of adults participating in a P1T consistently reflected 
courageous coping in attempting the unknown as well as in managing any resulting 
consequences.10,28,111 For many adult patients, P1T participation fulfilled their need to 
have tried everything to fight their cancer.7,10,28,111 Some courageous coping strategies, 
including maintaining normalcy and control over daily life, spending time with family, 
and focusing on QOL, were important to children with cancer and their parents 
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considering participation in a P1T.17,19 No other data was available for children 
participating in P1Ts.  
2.5.d Interactions of Defensive and Courageous Coping Factors 
Haase’s Resilience in Illness Model that defensive coping strategies are most 
prevalently used when individuals are highly threatened, until courageous coping 
strategies can be developed to address the threat.91 As such, defensive coping strategies 
only become problematic when used exclusively and for prolonged periods of time, 
without development of courageous coping strategies.91  
Although the optimism associated with clinical trial participation was potentially 
beneficial for both adult and pediatric P1T participants (a courageous coping strategy), 
potential harm could be created by unrealistic optimism (a defensive coping 
strategy).15,18,41,80,115 Unrealistic optimism is a belief, regardless of the quality and clarity 
of information communicated regarding a P1T, that one has a greater chance of 
personal benefit from P1T participation than any other patient.74,116 All P1T participants 
(or their parents / guardians) sign an informed consent document acknowledging their 
understanding of the nature of the P1T. Despite this, there was a high level of evidence 
that adult and pediatric P1T participants and their families thought and acted like the 
P1T therapy would improve, or even cure, their cancer.18,19,23,24,27,41,114,116 Unfortunately, 
for adult participants, expectations for tumor response and symptom improvement 
generally were not met during P1Ts.11,110,112,117 However, it is unclear how significant a 
problem unrealistic optimism was for P1T participants.115,116,118 There was evidence that 
adult P1T participants were able to be realistic about their prognosis and yet still 
hopeful about the P1T, which supports Weisman’s assertion that patients may be 
simultaneously accepting and denying the dying experience.10,28,114,119-121  
There was some evidence of both defensive and courageous coping strategies 
being used by adult P1T participants at trial conclusion. Trial conclusion was a 
particularly difficult time for most adult P1T participants because it signaled cancer 
progression and was accompanied by a loss of optimism.4,7,10,11,43,111 Despite this, there 
was evidence that at trial conclusion adult P1T participants maintained hope that others 
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would be helped by their participation in the P1T.7,11,43 At trial conclusion, adult P1T 
participants also coped with disappointment that the P1T did not work for them, relief 
that they no longer had to manage the P1T burdens, a loss of control when the decision 
to leave the P1T was made for them by healthcare providers / researchers, and fear of 
abandonment by the medical experts who had been caring for them.4,10,11,43,111 No data 
were available regarding children’s experiences at trial conclusion.  
 The articles describing adults’ P1T experiences included discussion regarding 
whether P1T participation represented ‘survival work’ and hence detracted from ‘death 
work’.7,10,41 Survival work refers to the cognitive and behavioral tasks involved with 
choosing to seek further treatment to improve and / or cure one’s disease, versus 
letting it take its natural course.28 Death work consists of the tasks involved with 
preparing for one’s death practically, emotionally, socially and spiritually.122 
Unfortunately, most P1T participants died during or shortly after trial conclusion; adult 
P1T participants engaged in significant survival work and therefore lost opportunities to 
complete death work.7,28,112 This trade-off in survival and death work was another 
example of the interaction between courageous and defensive coping strategies, as P1T 
participants’ survival work reflected courageous coping, while the simultaneous 
avoidance of death work reflected defensive coping.  
The idea that death work may be altered by P1T participation was founded in 
Glaser and Strauss’ recognition that dying involves a psychological process of 
adjustment, and the most crucial phase in the dying process occurs with recognition 
that a cure is not possible, and that death will occur in the foreseeable future.123,124 
However, instead of viewing P1T participation as lost time where death work wasn’t 
completed, P1T participation may better be viewed as one of the different trajectories 
that can be taken in the dying process.7,10 There was no evidence that adult P1T 
participants would have engaged in death work absent P1T enrollment.7,10 Indeed, there 
was some limited evidence that adult patients who participated in a P1T more 
frequently enrolled in hospice and were more likely to die at home or in hospice, and 
that the end-of-life care provided to children with cancer who participated in a P1T did 
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not differ from non-P1T participants at a large medical center with an active palliative 
care program.26,125 
In the pediatric literature, the impact of P1T participation on death work had 
only been minimally studied. There was some evidence that parents of children with 
cancer were only able to consider non-curative options, such as hospice, after accepting 
that their child could not get better.20,23 Ethicists and clinicians hypothesized that the 
participation of children with cancer in P1Ts not only alters their own death work, but 
also the grief work of their parents (who serve as proxy decision-makers).14,41 The child’s 
P1T participation theoretically minimized parents’ ability to engage in anticipatory 
grieving and prepare for their child’s death, potentially leading to more incidences of 
complicated bereavement.41 There was some evidence that although partners of adult 
P1T participants did not generally regret participating in the P1T, two years after the 
participant’s death they experienced more depression, psychological distress, 
complicated grief and decreased social and mental functioning compared to population 
norms.126  
2.5.e Protective Factor: Social Integration  
Overall, the pediatric and adult articles generally reinforced the importance of 
strong social support (which includes the support of friends, health care providers, and 
the community) to the patient’s well-being.88,90,91 There was limited evidence that adult 
P1T participants reported higher levels of social integration than non-participants.101 
Although the lack of pediatric research lessened an understanding of how P1T 
participation impacted children’s social integration, there was strong evidence that 
pediatric P1T participants were included in decision-making discussions with healthcare 
providers.24,27  
Cox described the ‘therapeutic alliance’ that was formed between adult P1T 
participants and healthcare providers, where participants benefited from the sense of 
everyone working together to actively fight their cancer.4,10 There was a strong level of 
evidence that adult P1T participants experienced enhanced support of high-quality 
healthcare and valued effective communication with healthcare providers.4,8,10,11,111,117 
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Indeed, adult P1T participants who traveled to a different geographic location to 
participate in the P1T were adversely affected by losing the support of their original 
healthcare providers.3 Adult P1T participants also experienced feelings of abandonment 
if their connection and shared goals with the P1T healthcare providers were lost at the 
end of trial participation.4,43,111 Adult P1T participants frequently experienced gaps in 
support and information at trial conclusion and would have benefited from assistance 
coping with being removed from the trial and transitioning back to their original 
healthcare providers.4,11,42,43,117 No empirical data on the impact of the therapeutic 
alliance with health care providers was available for children participating in P1Ts.  
An important societal influence prevalent in Western culture is the expectation 
that people with cancer are to be brave and to fight to overcome their cancer.10 There 
was some limited evidence that this societal expectation could influence adults’ 
participation in a P1T, since stopping treatment could be socially discouraged as giving-
in and losing hope.10,11 The impact of societal influences on P1T participation was not 
explored in the pediatric articles, however such influences represented a potential 
threat to social integration as a protective factor.  
2.5.f Protective Factor: Family Environment 
Family environment was generally accepted as important to P1T participants’ 
well-being, however there was minimal empirical work on the role and impact of family 
during the P1T experience.11,17,21,112,113,117 There was some evidence that the inclusion of 
the adult participant’s family when developing the P1T plan of care enhanced 
communication.11,117 Adult participants expected increased support from their family 
during the P1T and tended to receive support beyond those expectations.117 There was 
also some evidence that traveling away from family to participate in a P1T adversely 
affected the well-being of adult P1T participants.3 Kessler et al.127 found that caregivers 
of adult P1T participants reported high levels of distress, anxiety, and depressive 
symptoms, suggesting that enrollment in a P1T places a considerable burden on family 
and caregivers in terms of scheduling and managing the patient’s care. No empirical 
family environment data was available for children participating in P1Ts.  
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Double-protection was identified in the pediatric articles, reflecting a potential 
threat to the protection offered by the family environment. Double-protection is a 
phenomenon wherein both parent and child attempt to protect each other from 
distress, which while based in the intention to be supportive, reflects an evasion of open 
communication.128 Barrera et al. and Hinds et al. both provided empirical evidence that 
children who had recently been enrolled in a P1T demonstrated an awareness of the 
advanced state of their cancer and of their parents’ emotional turmoil.17,19 This 
suggested that the child’s assent to participate in a P1T may not have solely reflected 
their own desires, but may be influenced by a desire to ease their parents’ suffering or 
to acquiesce to their parents’ wishes.17,19  
2.5.g Protective Factor: Derived Meaning 
For children and adults with cancer, there was a high level of evidence that P1T 
participation offered hope that positively influenced well-being.4,7,10,11,17,28,111,113,114,121 
Adult P1T participants attributed meaning to simply being offered the opportunity to 
participate in a P1T; the offer engendered feelings of being special and chosen because 
only a few individuals were extended the opportunity.4,5,7,28,114 However, parents who 
were considering enrolling their child in a P1T struggled to balance hope for a cure with 
the potential negative impact of the P1T on their child’s well-being.17  
When prematurely removed from a P1T due to disease progression or toxicities, 
adult P1T participants lost hope for stabilization of cancer and / or symptom 
improvement.7,11,43  Yet although adult P1T participants experienced feelings of despair 
at this time, there was also evidence they maintained some degree of hope that others 
would be helped by their participation in the P1T.7,11,17,43 Even if not personally 
benefiting from the P1T, adult participants generally did not regret participating in the 
trial. Having the opportunity to try a novel treatment, to help themselves, to help 
others, and to contribute to future scientific advances, all provided meaning for adults’ 
P1T experiences.4,11,110,113,114,117,121 No data were available for children’s experiences at 
trial conclusion.  
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Other findings related to the use of hope and spirituality to find meaning 
included Daugherty et al.’s findings that adult P1T participants had higher levels of 
spirituality than non-participants and that P1T participants most commonly used a 
collaborative religious style of problem-solving.119 In addition, parents who were offered 
the option of a P1T for their child with cancer held onto different forms of hope, 
including hope for a peaceful death.17 
2.5.h Outcome Factor: Well-Being 
Well-being includes positive health outcomes like global QOL, resilience 
resolution, and self-transcendence, yet QOL was the only well-being outcome assessed 
in the articles.88 For adult P1T participants, QOL was focused on the ability to function, 
be productive, and free from symptoms of disease and treatment side-effects.3,11,112 In 
adult participants, no significant changes were found in overall QOL scores over one 
course of P1T therapy.6,12,101,102 There was some evidence that older adults participating 
in P1Ts established their QOL by comparison with their own prior treatment experiences 
and health, and by social comparison with peers.3,9 Even though there was minimal 
empirical evidence regarding whether the QOL or well-being of children or their families 
was impacted by P1T participation, there was a high level of evidence that QOL was a 
contributing factor to the decision to participate in a pediatric oncology P1T.17-21,23,24 
2.6 DISCUSSION OF FINDINGS 
2.6.a Primary Purpose: Synthesize and Appraise Evidence 
Overall, this review established that there is minimal empirical evidence 
regarding the experiences or well-being of children with cancer or their families in a P1T, 
beyond the process of consenting to the P1T. This lack of pediatric-focused research 
restricts our understanding of the impact of pediatric oncology P1T participation on the 
well-being of child participants and their families. However, meta-analyses and 
empirical studies focused on adult P1T participants and the pediatric oncology P1T 
consent process provided additional insights. Although the prognosis for children 
enrolled in a P1T is poor, these trials are generally safe, have manageable toxicities, and 
offer some hope for at least stabilization of disease for several months. 
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The Resilience Framework highlights that risk factors impacting the well-being of 
children with cancer include illness-related distress and defensive coping; whereas 
protective factors include courageous coping, derived meaning, social integration, and 
family environment.88 Per review findings, P1T-related treatment burdens may include 
increased hospital visits, additional medical procedures and tests, toxicities related to 
the novel therapy, logistical problems such as transportation and parking, and financial 
cost. The role of strong family and social support in fostering the patient’s well-being is 
well-recognized. It is important to also recognize the burden that P1T participation 
places on family members, and that travel away from family and friends to participate in 
a P1T may adversely affect the well-being of P1T participants.  
 As P1T participation focuses providers’, patients’, and families’ attention on 
survival work (courageous coping), review findings suggest participation may foster 
avoidance of death work (defensive coping) that could negatively impact the child’s 
dying process and /or the family’s bereavement. However, defensive coping strategies 
only become problematic when used exclusively for long periods of time, without 
development of courageous coping strategies.91 Courageous coping strategies may be 
supported through P1T participation by providing a sense of trying everything, allowing 
participants to form a therapeutic alliance with healthcare providers, representing a 
contribution to cancer research, and providing a purpose and meaning for their lives.  
Although not explored in the pediatric articles, further research is warranted 
regarding whether children or their parents feel compelled to battle their cancer 
heroically, to live up to societal – and perhaps familial - expectations. The unnaturalness 
of death in children and the fact that multiple stakeholders (i.e. child, parents, and 
providers) need to come to an agreement to stop curative attempts, are other potential 
societal influences on the decision to participate in a pediatric oncology P1T. Double-
protection may be particularly influential to children’s participation in a P1T as they seek 
to ease their parents’ suffering or to acquiesce to their parents’ wishes, due to the vital 
importance of the parent-child relationship for children.129  
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2.6.b Secondary Purpose: Gaps in Knowledge 
Insights were gained from research on the experience of adult P1T participants, 
however adult experiences are not directly applicable to the pediatric population. As 
demonstrated in Table 2.2 and Table 2.3, the reviewed articles employed a wide variety 
of research designs. The methods used to research the experience of adult P1T 
participants may be helpful to guide future research with pediatric participants. A 
unique challenge of researching experiences of P1T participants is that poor patient 
prognoses and disease progression results in decreased participant retention and 
completion of study procedures at later timepoints. A limitation of relying solely on 
quantitative QOL measures is that adult P1T participants’ ratings on QOL measures 
differed substantively from what these same participants reported during qualitative 
interviews.6,111 
From the adult focused articles, the work of Dr. Karen Cox is noteworthy in that 
it provides an exemplar of how research on adult experiences in P1Ts proceeded from 
initial descriptive studies to testing an intervention in an experimental study.4-7,42,111,130 
Dr. Cox’s research began with a small, longitudinal qualitative pilot study.111 After 
identifying areas of potential concern in the P1T experience, she then conducted a 
larger-scale longitudinal study with 55 adult P1T participants.4,6 Based on this second 
study, the transition off a P1T was identified as a significant area for intervention. Dr. 
Cox then developed a nurse-led intervention to improve patient management at the 
end of P1T participation, which was tested in a randomized, pre-post intervention 
study.48,7  
2.6.c Limitations of the Review 
Literature searches were limited to English language articles. In addition, use of a 
different framework than the Resilience Framework to synthesize findings would have 
resulted in a different organization of findings. Lastly, article evaluations were 
susceptible to bias as the researchers were not blinded to authors, journal, or 
publication year.  
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2.7 IMPLICATIONS FOR NURSING PRACTICE AND RESEARCH 
Review findings have implications for nurses and healthcare providers who work 
with children and families considering pediatric oncology P1Ts. The idea that a child’s 
assent to participate in a P1T may not solely reflect their own desires, but instead may 
be influenced by a desire to ease their parents’ suffering or by family and societal 
expectations, warrants particular attention. Children should have an active voice in the 
decision to participate in the P1T, and be directly addressed in consent discussions at an 
appropriate developmental level.129,131,132 Communication during P1T consent 
conversations is often inadvertently falsely reassuring.133 The impact of P1T 
participation on QOL and well-being, as outlined in this review, should be included in 
consent discussions, as well as the option of stopping treatment and focusing solely on 
palliative care.81,133 
2.8 CONCLUSIONS 
The experience and effects of P1T participation on children and families need to 
be better understood to uphold the ethical principles outlined in the Declaration of 
Helsinki.44 By understanding the impact of P1T participation on participants’ well-being, 
P1T researchers can acknowledge participants’ contributions, incorporate participants’ 
views into P1T management, enhance future participants’ preparedness, and ensure 
care is effectively provided throughout the P1T experience.5 Further research is needed 
that focuses on understanding the impact of participating in a P1T on the well-being of 
children and their families, in order to address gaps in current knowledge and ensure 
the P1T experience does not inadvertently impact the well-being of participating 
children with cancer and / or their families. 
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FIGURE 2.1  RESILIENCE FRAMEWORK  
(Reprinted with permission)88,89 
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FIGURE 2.2  PRISMA FLOW DIAGRAM 
  
 28 
TABLE 2.1  DEFINITION OF FACTORS FROM THE RESILIENCE FRAMEWORK 
(Reprinted with permission)88 
Risk 
Factors 
Illness- Related 
Distress  
The degree of perceived illness-related uncertainty, 
disease- and symptom- related distress, and 
burdens associated with treatment for disease. * 
Defensive Coping 
The degree to which the patient/family member 
uses evasive and emotive coping strategies to deal 
with the cancer experience. 
Protective 
Factors 
Courageous 
Coping 
The degree to which the patient/family member 
uses confrontive, optimistic, and supportant coping 
strategies to deal with the cancer experience. 
Social Integration 
The degree to which the patient/family perceives a 
sense of connectedness with and support from 
friends and healthcare providers. 
Family 
Environment 
The degree to which the patient/family member 
perceives the family as adaptable, cohesive, 
effectively communicating, and having family 
strengths. 
Derived Meaning 
The degree to which the patient/family member 
uses hope and spiritual perspective to derive 
meaning from the cancer experience. 
Outcome 
Factor Well-Being 
The process of identifying or developing resources 
and strengths to flexibly manage stressors to gain a 
positive outcome, a sense of confidence/ mastery, 
self- transcendence, and self-esteem. 
 
* Treatment burden was added as an additional indicator of Illness-Related Distress  
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TABLE 2.2  FINDINGS AND EVALUATION OF PEDIATRIC ARTICLES 
Author / Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to 
P1T Experience Ri
go
r 
Re
le
va
nc
e 
Barrera et al.17 / 
Health-Related 
Quality of Life and 
Enrollment in Phase I 
Trials in Children with 
Incurable Cancer  
To investigate 
health-related 
QOL in children 
eligible for P1Ts 
and the reasons 
why families 
participate in 
these trials 
Nine families of 
children with 
cancer 
presented the 
option of a P1T 
at a Canadian 
hospital 
• Qualitative 
study 
• Individual 
semi-
structured 
interviews 
with parents 
and children 
• Key components to 
health-related QOL 
were maintaining 
normalcy and control, 
information sharing, 
and having hope for life  
• Hope for a cure and 
prolonging the child’s 
life were the main 
reasons for enrolling in 
P1Ts 
M
ed
iu
m
 
Hi
gh
 
Bautista et al.39 / 
Patients in Pediatric 
Phase I and Early 
Phase II Clinical 
Oncology Trials at 
Gustave Roussy: A 
13-Year Center 
Experience 
To describe the 
experience in 
clinical new drug 
development in 
pediatric 
oncology at 
Gustave Roussy  
All solid tumor 
patients below 
the age of 21 
who enrolled in 
a phase I 
(n=106) or II 
trial (n=154) 
from 2000 - 
2012 
Meta-analysis 
of previously 
reported 
phase I and 
phase II clinical 
trial results 
• Phase I and II pediatric 
oncology trials are safe, 
associated with clinical 
benefit, and can be 
successfully integrated 
in current relapse 
strategies 
Hi
gh
 
M
ed
iu
m
 
Carlson et al.109 / 
Pediatric Phase I 
Drug Tolerance: A 
Review and 
Comparison of 
Recent Adult and 
Pediatric Phase I 
Trials 
To evaluate the 
ratio of pediatric 
to adult maximum 
tolerated doses 
from P1Ts  
70 P1Ts 
conducted from 
1975 - 1995, 
where pediatric 
and adult P1Ts 
could be 
matched 
Meta-analysis 
of previously 
reported P1T 
results 
• Pediatric patients have 
an equal or greater 
medication tolerance 
than adult patients 
enrolled on matched 
P1Ts 
• Patients on adult P1Ts 
are significantly less 
heavily pretreated than 
patients on matched 
pediatric P1Ts 
Hi
gh
 
Lo
w
 
Chang15 / 
An Exploratory 
Survey of Nurses' 
Perceptions of 
Phase I Clinical 
Trials in Pediatric 
Oncology 
To evaluate 
nurses’ 
perceptions of 
P1Ts 
43 nurses from 
a large North 
American 
hospital 
surveyed in 
2003 
Exploratory 
survey study 
using 
qualitative and 
quantitative 
questions 
• Nurses identified 
benefits of P1Ts as 
improving future 
therapies, QOL, disease 
burden, and hope, and 
negative outcomes as 
toxicities, false hope 
and decreased QOL 
Lo
w
 
M
ed
iu
m
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Author / Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to 
P1T Experience Ri
go
r 
Re
le
va
nc
e 
Cousino et al.27 / 
Communicating and 
Understanding the 
Purpose of Pediatric 
Phase I Cancer 
Trials 
To investigate 
physician-parent 
communication 
during informed 
consent 
conferences and 
parental 
understanding of 
the P1T purpose 
85 P1T 
informed 
consent 
conferences 
and 60 follow-
up parent 
interviews 
conducted at six 
hospitals from 
2008 - 2011 
• Multi-site, 
prospective 
study 
• Quantitative 
analysis of 
qualitative 
data from 
recorded 
informed 
consent 
conferences 
and parent 
interviews 
• After informed consent 
conferences, many 
parents do not 
understand the 
scientific purpose of 
P1Ts 
• Physician explanations 
during informed 
consent conferences did 
not ensure parental 
understanding 
• Child attended 83 of 85 
observed informed 
consent conferences 
Hi
gh
 
Lo
w
 
Deatrick et al.18 / 
Parents’ Views of 
their Children’s 
Participation in 
Phase I Oncology 
Clinical Trials 
To describe 
parents’ views 
about their 
children’s 
participation in 
P1Ts  
21 parent 
interviews 
following a P1T 
decision, taken 
from a 
prospective 
study of end-of-
life decision-
making 
Secondary, 
qualitative 
analysis of 
data from a 
prospective, 
descriptive 
study of 
pediatric 
oncology end-
of-life 
decision-
making  
• All parents saw limited 
choice in the decision 
whether to enter their 
child in the P1T 
• Parent expectations of 
trial participation 
included providing 
treatment, buying time, 
working a miracle, being 
altruistic, and delaying 
death 
• Parental circumstances, 
including practical 
issues, the child’s 
capacity and spirituality, 
were important to 
perceptions of P1T 
participation  
Hi
gh
 
M
ed
iu
m
 
Furman et al.37 / 
Mortality in 
Pediatric Phase I 
Clinical Trials 
To determine the 
risk of fatal 
toxicity and 
objective 
response rate in 
pediatric P1Ts 
577 pediatric 
enrollments on 
30 P1Ts at one 
hospital from 
1967-1989  
Meta-analysis 
of previously 
reported P1T 
results  
• Well-planned phase I 
clinical trials do not 
expose children to an 
undue risk of fatal 
toxicity and offer slight 
hope for a therapeutic 
effect 
Hi
gh
 
Lo
w
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Author / Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to 
P1T Experience Ri
go
r 
Re
le
va
nc
e 
Hinds et al.19 / 
End-of-Life Care 
Preferences of 
Pediatric Patients 
with Cancer 
To identify 
preferences of 
children / 
adolescents with 
cancer about 
their end-of-life 
care and the 
factors that 
influenced their 
decisions 
20 pediatric 
patients (>10 
years), their 
parent, and 
their primary 
oncologist 
interviewed 
after making an 
end-of-life 
decision 
• Qualitative, 
prospective 
study 
• Individual, 
open-ended 
interviews 
with patient, 
parent and 
oncologist 
within 7 days 
of end-of-life 
decision 
• Children / adolescents 
with cancer realized 
they were involved in 
an end-of-life decision, 
understood the 
consequences, and 
were capable of 
participating in the 
decision 
• Consideration of others’ 
preferences was the 
most frequently 
reported decision-
making factor by 
patients, parents, and 
physicians 
Hi
gh
 
Lo
w
 
Hinds et al.20 / 
Decision Making by 
Parents and 
Healthcare 
Professionals when 
Considering 
Continued Care for 
Pediatric Patients 
with Cancer 
To define the 
treatment-
related decisions 
considered most 
difficult by 
parents of 
pediatric patients 
and the factors 
that influenced 
decisions 
39 parents of a 
child with 
cancer 
deceased in the 
previous 6-24 
months and 
their child’s 
primary 
provider 
• Mixed 
methods 
retrospective 
study 
• Individual, 
semi-
structured 
interviews 
with parent 
and provider 
• Parents and healthcare 
professionals cite 
similar decision-making 
factors, but differ in 
their rating of the 
factors’ importance 
• Once parents conclude 
their child cannot get 
better, they are more 
likely to choose non-
curative options 
Hi
gh
 
Lo
w
 
Hinds et al.21 / 
"Trying to be a 
Good Parent" as 
Defined by 
Interviews with 
Parents who made 
Phase I, Terminal 
Care, and 
Resuscitation 
Decisions for their 
Children 
To define being a 
good parent to a 
child with 
incurable cancer 
62 parents (of 
58 children) 
who made an 
end-of-life 
decision in the 
last 72 hours for 
their child with 
cancer 
• Qualitative 
study using 
semantic 
analysis 
• Individual 
open-ended 
interviews 
with parent 
• Being a good parent 
means making 
informed, unselfish 
decisions in the child’s 
best interest, remaining 
at the child’s side, 
showing the child they 
are cherished, teaching 
the child to make good 
decisions, advocating 
for the child with staff, 
and promoting the 
child’s health 
Hi
gh
 
Lo
w
 
Kim et al.2 / 
Characteristics and 
Outcome of 
Pediatric Patients 
Enrolled in Phase I 
Oncology Trials 
To describe the 
characteristics of 
children enrolled 
in P1Ts, find 
associations 
between 
characteristics 
and toxicity risk, 
and analyze 
outcomes 
262 patients 
enrolled on 16 
different P1Ts 
coordinated by 
National Cancer 
Institute from 
1992-2005 
 Meta-analysis 
of previously 
reported P1T 
results  
• Approximately 90% of 
P1T participants were 
evaluable for study 
endpoints 
• P1Ts are safe with 
manageable toxicities 
• Therapy dose was most 
strongly associated with 
dose-limiting toxicities  
• Median overall survival 
time after enrollment 
was 5 months 
Hi
gh
 
M
ed
iu
m
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Author / Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to 
P1T Experience Ri
go
r 
Re
le
va
nc
e 
Lee et al.1 / 
Pediatric Phase I 
Trials in Oncology: 
An Analysis of Study 
Conduct Efficiency 
To determine the 
efficacy and 
safety of 
pediatric 
oncology P1Ts 
and to analyze 
how efficiently 
these trials are 
conducted 
69 P1Ts 
enrolling 1,973 
patients 
between 1990-
2004  
Meta-analysis 
of previously 
reported P1T 
results 
• P1Ts continue to be safe 
and relatively well-
tolerated 
• Deriving direct benefit 
from a P1T should not 
be equated with 
observed response rate 
• Types of toxicities 
experienced by children 
were similar to those 
experienced by adults 
Hi
gh
 
Lo
w
 
Levine et al.26 /  
Does Phase 1 Trial 
Enrollment Preclude 
Quality End-of-Life 
Care? Phase 1 Trial 
Enrollment and 
End-of-Life Care 
Characteristics in 
Children with 
Cancer 
To determine 
whether end-of-
life 
characteristics 
differed between 
pediatric 
oncology patients 
who were and 
were not 
enrolled in a P1T 
277 children 
with solid 
tumors who 
were (n=120) 
and were not 
(n=157) enrolled 
in a P1T and who 
died between 
2001-2005 
• Quantitative, 
cohort 
secondary 
analysis 
• Retrospective 
chart review 
• No significant 
differences were found 
in use or timing of do 
not attempt 
resuscitation orders, 
hospice use or length of 
stay, forgoing life-
sustaining therapies, 
location of death, time 
from first end-of-life 
care discussion to 
death, and total number 
of end-of-life care 
discussions 
• Enrollment on a P1T 
does not affect end-of-
life care characteristics  
Hi
gh
 
M
ed
iu
m
 
Marshall et al.22 / 
Negotiating 
Decisions during 
Informed Consent 
for Pediatric Phase I 
Oncology Trials 
To identify key 
communication 
steps and factors 
that influence the 
negotiation of 
decisions 
regarding P1T 
participation 
16 informed 
consent 
conversations 
selected by 
stratified 
random 
selection from 
49 informed 
consent 
conversations 
from 2008-2011 
Secondary, 
qualitative, 
grounded 
theory analysis  
• During informed 
consent conversations, 
families, patients, and 
clinicians exercise 
choice and control by 
negotiating micro-
decisions in two broad 
domains: drug logic and 
logistics, and 
administration / 
scheduling 
 
M
ed
iu
m
 
M
ed
iu
m
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Author / Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to 
P1T Experience Ri
go
r 
Re
le
va
nc
e 
Maurer et al.23 / 
Decision Making by 
Parents of Children 
with Incurable 
Cancer who Opt for 
Enrollment on a 
Phase I Trial 
Compared with 
Choosing a Do Not 
Resuscitate / 
Terminal Care 
Option 
To compare the 
self-reported 
rationale, good 
parent definition 
and desired 
clinical staff 
behaviors of 
parents who 
decided on P1T 
participation with 
parents who 
chose a DNR / 
terminal care 
option 
62 parents (of 
58 children) 
who made an 
end-of-life 
decision in the 
last 72 hours for 
their child with 
cancer 
• Qualitative 
study using 
semantic 
analysis 
• Individual 
open-ended 
interviews 
with parent 
and 
demographic 
data from 
chart 
• Despite similar 
definitions of a good 
parent and desired staff 
behaviors, parents 
choosing to participate 
in a P1T reported 
feeling compelled to 
continue cancer-
directed therapy, 
whereas parents 
choosing DNR and 
terminal care options 
reported an emphasis 
on QOL and patient 
wishes 
• No parent chose both 
participation in a P1T 
and a DNR / terminal 
care option 
Hi
gh
 
M
ed
iu
m
 
Miller et al.24 /  
Adolescent 
Perspectives on 
Phase I Cancer 
Research 
To examine 
adolescent 
patient 
perspectives on 
their 
understanding 
and decision-
making about a 
P1T 
20 structured 
interviews of 
adolescents 
with cancer 
who attended a 
P1T informed 
consent 
conversation 
between 2008-
2011 
• Prospective 
study 
• Quantitative 
analysis of 
qualitative 
data from 
recorded 
informed 
consent 
conferences 
and 
interviews 
• Most adolescents 
understood P1T was 
voluntary, entailed 
risks, and they could 
withdraw  
• Reasons for enrolling 
were positive clinical 
benefit, needing an 
option, impact on QOL, 
and fewer side than 
other treatments 
• Most participants 
hoped or expected that 
P1T would provide a 
direct benefit and 
reported that they 
made the final decision 
to enroll in P1T 
Hi
gh
 
M
ed
iu
m
 
Morgenstern et al.40 
/  
Toxicity and 
Outcome of 
Children and 
Adolescents 
Participating in 
Phase I/II Trials of 
Novel Anticancer 
Drugs: The Royal 
Marsden 
Experience 
To produce an 
overview of 
outcomes and 
toxicities for 
pediatric patients 
recruited to early 
phase trials from 
2002 to 2011 
66 patients who 
enrolled and 
were treated in 
a phase I (n=24) 
or II trial (n=42) 
from 2002-2011  
Meta-analysis 
of previously 
reported 
phase I and 
phase II clinical 
trial results 
• Early phase trials in 
children are safe and 
unexpected toxic side 
effects are infrequent, 
although the overall 
prognosis for these 
individuals is poor 
• Patients and their 
families are willing to 
travel to access novel 
therapies 
M
ed
iu
m
 
M
ed
iu
m
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Author / Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to 
P1T Experience Ri
go
r 
Re
le
va
nc
e 
Oppenheim et al.25 
/  
Ethical Issues in 
Pediatric Oncology 
Phase I-II Trials 
Based on a 
Mother’s Point of 
View 
To present and 
discuss the 
complex 
relational, 
psychological and 
ethical issues 
regarding P1T 
participation 
1 parent 
interview with a 
psycho-
oncologist 
following the 
decision to 
participate in a 
P1T 
Case report • Decisions regarding P1T 
participation are easier 
when all parties 
involved are aware of 
motivations, 
expectations, and 
accept the inherent 
risks  
• Physicians in charge of 
clinical care and 
research should be 
different, to ensure 
child’s interests take 
precedence over that of 
research 
Lo
w
 
M
ed
iu
m
 
Paoletti et al. 36 /  
A Comparative 
Analysis of 
Paediatric Dose-
Finding Trials of 
Molecularly 
Targeted Agent 
with Adults’ Trials 
To assess the 
objectives, place 
and role of P1Ts 
in the era of 
molecularly 
targeted agents 
19 single agent 
pediatric P1Ts 
of molecularly 
targeted agents 
approved in 
adults before 
6/15/2012 
Meta-analysis 
of previously 
reported P1T 
results 
• 63% of pediatric 
patients are treated at 
suboptimal doses of 
molecularly targeted 
agents (less than the 
maximum tolerated 
dose)  
• Safety profiles 
described by pediatric 
P1Ts of molecularly 
targeted agents were 
usually similar to the 
adult population 
Hi
gh
 
Lo
w
 
Shah et al. 38 / 
Phase I Therapy 
Trials in Children 
with Cancer 
To examine the 
response and 
toxicity rates of 
therapies 
evaluated in P1Ts 
to identify trends 
in response and 
toxicity over time 
56 P1Ts 
enrolling 1,606 
patients 
between 1978 
and 1996 
Meta-analysis 
of previously 
reported P1T 
results 
• P1Ts are a safe 
mechanism to 
determine the 
maximum tolerated 
dose, toxicity profile, 
and pharmacokinetics 
of new agents  
• Methods of assessing 
response do not 
routinely consider 
stable disease, 
improvements in pain 
control, or QOL, even 
though these are 
meaningful to patients 
and families 
M
ed
iu
m
 
M
ed
iu
m
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TABLE 2.3  FINDINGS AND EVALUATION OF ADULT ARTICLES 
Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to P1T 
Experience Ri
go
r 
Re
le
va
nc
e 
Berdel et al.101 / 
Influence of Phase I 
Early Clinical Trials 
on the Quality of 
Life of Cancer 
Patients: A Pilot 
Study 
To assess the 
impact of phase I 
trials on the QOL 
of cancer 
patients versus 
patients treated 
with low efficacy 
1-2 medication 
regimens off-
study 
18 patients 
treated in 
P1Ts and 8 
patients 
treated with 
low efficacy 
1-2 
medication 
regimens off-
study 
• Quantitative, 
cohort pilot 
study  
• Linear Analog 
Self-
Assessment 
and Karnofsky 
Performance 
Score used to 
assess QOL at 
four timepoints 
• No significant negative 
QOL influence in P1T 
group  
• Slight positive influence 
of P1T in terms of self-
assessed social activity 
and performance score 
• In both groups, there was 
a significant positive 
influence of overall 
anticancer medication on 
psychological and social 
aspects of QOL  
M
ed
iu
m
 
M
ed
iu
m
 
Campbell et al.112 / 
The Quality of Life 
of Cancer Patients 
Participating in 
Phase I Clinical 
Trials Using SEIQoL-
DW 
To examine the 
QOL of cancer 
patients 
participating in 
P1Ts, and to 
determine the 
acceptability of 
the QOL 
instrument  
15 adult 
cancer 
patients 
participating 
in a P1T 
during 4-
week 
recruitment 
period in 
1997 
• Quantitative 
study  
• One individual, 
semi-
structured 
interview using 
the Schedule 
for the 
Evaluation of 
Individual QOL 
–Direct 
Weighting 
(SEIQoL-DW)  
• Health and family were 
particularly important to 
in relation to patient’s 
QOL 
• QOL instrument was 
found to be acceptable 
and practical to use with 
P1T participants  
 
M
ed
iu
m
 
M
ed
iu
m
 
Carlson et al.121 /  
Individualized 
Quality of Life, 
Standardized 
Quality of Life, and 
Distress in Patients 
Undergoing a 
Phase I Trial of the 
Novel Therapeutic 
Reolysin 
To evaluate the 
individualized 
and 
standardized 
QOL and 
psychological 
distress of 
patients 
participating in a 
P1T of the novel 
therapeutic 
reovirus 
16 adult 
cancer 
patients 
interviewed 
prior to being 
accepted 
into the 
phase I trial 
• Mixed methods 
study 
• One individual, 
semi-
structured 
interview of 
health 
expectations 
where 
standardized 
QOL, distress, 
and spirituality 
instruments 
were 
completed 
• Patients felt hopeful and 
excited about the trial, 
with about two thirds 
hoping for disease 
regression and one third 
hoping for a cure 
• Patients reported less 
psychopathology than 
would be expected of 
patients in similar 
disease states, but 
comparable to cancer 
patients in general, and 
overall mild depressive 
symptomatology 
Lo
w
 
M
ed
iu
m
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Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to P1T 
Experience Ri
go
r 
Re
le
va
nc
e 
Cohen et al.3 / 
Phase I 
Participants’ Views 
of Quality of Life 
and Trial 
Participation 
Burdens 
To assess 
participants’ 
perception of 
experience on 
P1Ts including 
associated QOL  
First 100 
adult patients 
referred to a 
specified P1T; 
and 16 
patients 
enrolled in 
the P1T  
• Qualitative 
study  
• Qualitative 
survey 
completed by 
referred 
patients 
• Hermeneutic 
phenomenologi
cal interview 
with enrolled 
patients  
• Participants established 
their current QOL by 
comparison with prior 
cancer treatments  
• Indirect and procedural 
burdens of P1T 
participation had a 
significant impact on 
participants’ current QOL 
M
ed
iu
m
 
Hi
gh
 
Cox4 / 
Researching 
Research: Patients' 
Experiences of 
Participation in 
Phase I and II Anti-
Cancer Drug Trials 
To identify the 
psychosocial 
processes of 
participating in a 
phase I or II trial, 
ways of coping, 
and 
consequences of 
trial involvement 
55 adult 
patients 
enrolled in a 
phase I or II 
cancer clinical 
trial within a 
12-month 
recruitment 
period from 
1996-1997 
• Mixed 
methods, 
longitudinal 
study 
• Semi-
structured in-
depth 
interviews and 
instruments 
completed at 
four timepoints  
• Trial offer meant: hope, 
uncertainty, and being 
honored 
• Trial involved: burdens, 
being in expert hands, 
contributing to research, 
being special, having a 
purpose, and life on hold  
• Trial conclusion involved 
feelings of 
disappointment, relief, 
fear of abandonment, 
uncertainty, and 
preparations for death 
M
ed
iu
m
 
Hi
gh
 
Cox5 / 
Enhancing Cancer 
Clinical Trial 
Management: 
Recommend-
ations from a 
Qualitative Study 
of Trial 
Participants’ 
Experiences 
To propose 
empirically-
based 
recommendatio
ns for early 
phase cancer 
clinical trial 
management 
55 adult 
patients 
enrolled in a 
phase I or II 
cancer clinical 
trial within a 
12-month 
recruitment 
period from 
1996-1997 
• Mixed 
methods, 
longitudinal 
study 
•  Semi-
structured in-
depth 
interviews and 
instruments 
completed at 
four timepoints  
• Early phase trial 
participation is a dynamic 
process that has different 
meanings and impact per 
the stage of trial 
involvement 
• Need to enhance 
preparation of trial 
participants, establish 
continuing care post-
trial, and incorporate 
patients’ views 
M
ed
iu
m
 
M
ed
iu
m
 
Cox7 / 
The Hopes of the 
Dying: Examining 
Patients' 
Experience of 
Participation in 
Early Phase Cancer 
Clinical Trials 
To present a 
theoretical 
examination of 
hope and dying 
from a 
longitudinal 
qualitative study 
of the 
experience of 
phase I cancer 
clinical trial 
participation 
55 adult 
patients 
enrolled in a 
phase I or II 
cancer clinical 
trial within a 
12-month 
recruitment 
period from 
1996-1997 
• Mixed 
methods, 
longitudinal 
study  
• Semi-
structured in-
depth 
interviews and 
instruments 
completed at 
four timepoints  
• Hope and dying were the 
two major themes that 
emerged in relation to 
how patients 
experienced trials 
• By averting the 
immediate confrontation 
with death, trial 
involvement appeared to 
disturb some of the 
psychological processes 
and stages of dying 
M
ed
iu
m
 
Hi
gh
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Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to P1T 
Experience Ri
go
r 
Re
le
va
nc
e 
Cox6 / 
Assessing the 
Quality of Life of 
Patients in Phase I / 
II Anti-Cancer Drug 
Trials: Interviews 
versus 
Questionnaires 
To compare and 
contrast two 
different 
approaches to 
assessing QOL in 
the context of 
cancer clinical 
trial 
participation 
55 adult 
patients 
enrolled in a 
phase I or II 
cancer clinical 
trial within a 
12-month 
recruitment 
period from 
1996-1997 
• Mixed 
methods, 
longitudinal 
study  
• Semi-
structured in-
depth 
interviews and 
instruments 
completed at 
four timepoints  
• Data obtained from QOL 
questionnaires revealed 
no statistically significant 
differences in scores  
• Interviews uncovered 
some of the 
psychological, emotional 
and social impact of early 
phase clinical trial 
participation from the 
patient’s perspective 
M
ed
iu
m
 
M
ed
iu
m
 
Cox et al.111 / 
Psychosocial 
Aspects of 
Participation in 
Early Anticancer 
Drug Trials: Report 
of a Pilot Study 
To present the 
results of a pilot 
study exploring 
the psychosocial 
aspects of 
participation in 
an early phase 
clinical trial 
7 adult 
patients 
enrolled in a 
phase I or II 
cancer clinical 
trial during 
recruitment 
period 
• Mixed 
methods, 
longitudinal 
study  
• Semi-
structured in-
depth 
interviews and 
instruments 
completed at 
three 
timepoints  
• Patients consistently 
minimized their 
problems when filling in 
QOL questionnaires 
• Results suggest there 
were times when the 
process of trial 
participation was not 
acceptable to 
participants 
M
ed
iu
m
 
Hi
gh
 
Cox42 / 
A Randomised 
Controlled Trial of 
Nurse-Managed 
Trial Conclusion 
Following Early 
Phase Cancer Trial 
Participation 
To present the 
quantitative 
findings from a 
nurse-led 
strategy for 
improving the 
management of 
the conclusion of 
patients’ 
participation in a 
P1T 
117 patients 
(n=59 
intervention 
group, n=58 
control 
group) 
enrolled in 
any P1T at 
two medical 
centers 
within a 36-
month 
recruitment 
period from 
2001-2004 
• Randomized, 
pre-post mixed 
methods 
intervention 
study  
• Nurse 
intervention 
included P1T 
exit interview, 
leaflet, and 
follow-up call 
• Quantitative 
instruments 
completed at 
two timepoints 
with in-depth 
interview at 
second 
timepoint 
• No difference between 
groups in scores for 
anxiety and depression at 
trial conclusion 
• Patients in intervention 
group had statistically 
insignificant reduction in 
anxiety post intervention 
• Patients in intervention 
group were more 
satisfied with 
information given about 
the trial and with their 
follow up 
M
ed
iu
m
 
Lo
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Title Purpose Sample and Setting 
Design and 
Method 
Findings Related to P1T 
Experience Ri
go
r 
Re
le
va
nc
e 
Daugherty et al.119 / 
Trusting God and 
Medicine: 
Spirituality in 
Advanced Cancer 
Patients 
Volunteering for 
Clinical Trials of 
Experimental 
Agents 
To examine the 
role of 
spirituality in 
terminally ill 
cancer patients 
who volunteer 
for P1Ts 
162 cancer 
patients 
enrolled in a 
P1T from 
1997-1999 
and 156 
advanced 
cancer 
patients not 
participating 
in a P1T from 
1993-1996 
• Quantitative, 
cohort study 
• Spirituality, 
QOL, and 
decision-
making 
instruments 
were 
completed at 
one timepoint 
by P1T group; 
Control group 
participants 
and data were 
selected from a 
pre-existing 
data set 
• P1T group had slightly 
higher levels of 
spirituality than the 
control group  
• In P1T group, spirituality 
was positively associated 
with QOL 
• Spirituality was not 
associated with P1T 
patients’ awareness of 
their prognosis or 
decision-making 
preferences 
Hi
gh
 
M
ed
iu
m
 
Finlay et al.100 / 
Do Phase 1 
Patients Have 
Greater Needs for 
Palliative Care 
Compared with 
Other Cancer 
Patients?  
To define the 
palliative care 
needs of phase I 
patients and to 
determine 
whether their 
needs are 
greater than 
other cancer 
patients 
297 patients 
receiving 
cancer 
therapy and 
69 patients 
enrolled in 
P1Ts over a 
period of two 
years 
• Quantitative, 
cohort study 
• Instruments 
completed at 
one timepoint 
• Compared with other 
patients who had cancer, 
patients who were 
participating in P1Ts 
were less likely to want 
home care services, 
although they 
experienced a greater 
symptom burden 
• Groups differed 
significantly with respect 
to race 
M
ed
iu
m
 
M
ed
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George et al.104 / 
Sleep Quality and 
Its Association 
With Fatigue, 
Symptom Burden, 
and Mood in 
Patients With 
Advanced Cancer 
in a Clinic for Early-
Phase Oncology 
Clinical Trials 
To describe 
sleep quality and 
its relation with 
fatigue, 
symptom 
burden, and 
mood in patients 
recruited from 
an early-phase 
clinic for 
targeted therapy 
256 patients 
recruited 
from a phase 
clinical I trial 
clinic during 
the 16-month 
recruitment 
period 
• Quantitative, 
cross-sectional 
study 
• Instruments 
completed at 
one timepoint 
• Poor sleep quality was a 
significant problem in the 
current study and was 
associated with greater 
fatigue, symptom 
burden, and mood 
disturbance.  
• Sleep quality should be 
routinely assessed in 
patients with advanced 
cancer who are 
participating in early-
phase clinical trials. 
Hi
gh
 
M
ed
iu
m
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Design and 
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e 
Godskesen et al.114 / 
Phase 1 Clinical 
Trials in End-Stage 
Cancer: Patient 
Understanding of 
Trial Premises and 
Motives for 
Participation 
To explore and 
describe 
patients’ reasons 
for participation, 
their 
experiences 
related to P1T 
participation, 
and issues 
associated with 
the information–
consent process 
14 patients 
enrolled in 
one of three 
ongoing P1Ts 
during the 11-
month 
recruitment 
period from 
2011-2012  
• Qualitative, 
cross-sectional 
study 
• One individual, 
semi-
structured 
interview 
• Patients expressed 
unrealistic expectations 
of therapeutic benefit 
and inadequate 
understanding of P1T’s 
purpose 
• Patients valued the close 
and unique medical and 
psychological attention 
they received by 
participating. 
• Participation made 
patients feel unique and 
notable. 
M
ed
iu
m
 
Hi
gh
 
Helft et al.115 / 
Associations 
Among Awareness 
of Prognosis, 
Hopefulness, and 
Coping in Patients 
with Advanced 
Cancer 
Participating in 
Phase I Clinical 
Trials 
To examine the 
relationships 
among 
awareness of 
prognosis, 
hopefulness, 
and coping in a 
selected 
group of 
advanced cancer 
patients 
179 advanced 
cancer 
patients 
signing 
consent for a 
P1T within 
the 
recruitment 
period 
• Quantitative 
study 
• One individual, 
structured 
interview 
conducted 
within 7 days of 
the start of the 
P1T using both 
quantitative 
and semi-
quantitative 
instruments 
• Many patients reported 
an unrealistic view of 
their prognosis.  
• Having a more accurate 
view of prognosis in the 
face of terminal illness 
was associated with 
reduced hopefulness, 
which may be related to 
a poorer sense of coping. 
Lo
w
 
Lo
w
 
Hui et al.103 / 
Timing of Palliative 
Care Referral and 
Symptom Burden 
in Phase 1 Cancer 
Patients 
To compare 
timing of referral 
and symptom 
burden between 
patients referred 
to palliative care 
by phase I 
oncologists vs. 
non-phase I 
oncologists  
57 patients 
referred by 
phase I 
oncologists 
and 114 
patients 
referred by 
non-phase I 
oncologists 
from 2007-
2008 
• Quantitative, 
retrospective 
cohort study  
• Secondary 
analysis of data 
extracted from 
chart, including 
QOL 
instruments 
completed on 
referral to 
palliative care 
services  
• Patients referred by 
phase I oncologists had a 
better performance 
status but similar 
symptom burden 
compared to control 
group 
• Patients phase I 
involvement did not 
delay palliative care 
referral, but it did 
increase the likelihood of 
receiving chemotherapy 
in the last 30 days of life 
M
ed
iu
m
 
Lo
w
 
Hutchison8 / 
Phase I Trials in 
Cancer Patients: 
Participants' 
Perceptions 
To determine 
how cancer 
patients 
perceive P1Ts in 
reference to trial 
participation and 
information 
received 
28 adult 
patients 
receiving 
therapy on an 
oncology P1T 
during the 3-
month 
recruitment 
period 
• Quantitative 
study 
• One structured 
interview using 
a questionnaire 
with closed 
questions  
• Patients participated in 
P1Ts because they 
offered hope, yet 
expectations were still 
realistic 
• Benefits related to 
participating in P1Ts 
including amount and 
quality of nursing / 
medical care as 
compared to standard 
treatment  
Hi
gh
 
M
ed
iu
m
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Jansen et al.116 / 
Dispositional 
Optimism and 
Therapeutic 
Expectations in 
Early-Phase 
Oncology Trials 
To examine 
expectations for 
personal 
therapeutic 
benefit 
reported by 
patients in early-
phase oncology 
trials  
171 patients 
enrolled in a 
phase I or II 
trial at one of 
the 
participating 
cancer 
centers  
• Quantitative 
study 
• One structured 
interview using 
a questionnaire 
with closed 
questions 
• High expectations for 
therapeutic benefit 
should not be assumed 
to result from 
misunderstanding of 
specific information.  
• Unrealistic optimism, but 
not dispositional 
optimism, was 
significantly associated 
with therapeutic 
misconception.  
Hi
gh
 
Lo
w
 
Kessler et al.127 / 
Distress Among 
Caregivers of 
Phase I Trial 
Participants: A 
Cross-Sectional 
Study 
To assess the 
distress and 
emotion 
regulation of 
caregivers of 
P1T participants 
to inform the 
design of future 
interventions 
88 caregivers 
of patients 
enrolled in a 
P1T during 
the 
recruitment 
period 
• Quantitative 
cross-sectional 
pilot study 
• Self-
administered 
instruments 
completed at 
one timepoint 
between 
Course 1 Day 1 
and Day 15 of 
P1T  
• Caregivers exhibited 
greater distress than 
population norms.  
• Emotion regulation was 
also moderately 
impaired. 
• Caregivers identified 
positive aspects of 
caregiving despite 
exhibiting moderate 
distress. 
Hi
gh
 
M
ed
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Kvale et al.9 / 
The Experience of 
Older Patients 
With Cancer in 
Phase 1 Clinical 
Trials: A 
Qualitative Case 
Series 
To explore the 
experiences of 
older patients 
with cancer in 
P1Ts 
4 white older 
adults 
receiving 
treatment on 
a phase 1 
oncology 
clinical trial 
• Qualitative, 
hermeneutic 
phenomenolog
y study  
• One in-depth 
semi-
structured 
interview 
• Social comparison 
influences decisions to 
enroll in P1Ts, shapes 
perceptions of 
supportive care needs, 
and encourages use of 
hope 
• Social comparison can 
inhibit articulation of 
pain, suffering and 
symptom burden 
M
ed
iu
m
 
M
ed
iu
m
 
Langenberg et al.126 
/ 
How Did Partners 
Experience Cancer 
Patients' 
Participation in a 
Phase I Study? An 
Observational 
Study After a 
Patient's Death 
To explore 
partners' 
experience of 
patients' 
participation in 
P1Ts and to 
investigate their 
well-being after 
a patient's death 
58 Partners of 
deceased 
cancer 
patients who 
participated 
in a P1T from 
2007-2009 
• Quantitative 
study 
• Instruments 
completed at 
one timepoint 
by hand, using 
standardized 
instruments to 
assess well-
being and one 
novel 
instrument 
developed for 
study 
• Although partners 
reported negative 
consequences on 
patients' quality of life, 
most did not regret 
patients' participation in 
the P1Ts.  
• Depression, 
psychological distress, 
and complicated grief 
were important 
problems for partners 
after the patient's death. 
M
ed
iu
m
  
M
ed
iu
m
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e 
Mack110 / 
The Quest for 
treatment: Cancer 
Patients' 
Experience of 
Phase I Clinical 
Trials 
To explore, from 
the perspective 
of the patient, 
the essential 
structure of the 
lived experience 
of participating 
in P1Ts 
20 adult 
patients who 
consented to 
participate in 
an oncology 
P1T  
• Qualitative, 
longitudinal 
hermeneutic 
phenomenolog
y study  
• Two in-depth 
unstructured 
interviews 
• The overall theme that 
emerged was the Quest 
for Treatment 
• The Quest for Treatment 
was an active process, 
marked by typical steps 
along the way. These 
steps emerged as 
categories across the 
narratives: (a) Taking 
Charge, (b) Deciding, (c) 
Living on a Trial, and (d) 
Dealing with Uncertainty. 
Hi
gh
 
Hi
gh
 
Melink et al.102 / 
The Impact of 
Phase I Clinical 
Trials on the 
Quality of Life of 
Patients with 
Cancer 
To evaluate the 
QOL of cancer 
patients 
receiving 
cytotoxic phase I 
therapy 
45 patients 
treated in a 
P1T and 10 
patients 
found 
ineligible to 
be treated in 
a P1T from 
1983-1985 
• Quantitative, 
longitudinal 
pilot study  
• Linear Analog 
Self-
Assessment of 
QOL, 
performance 
status, and 
survival time 
assessed at two 
timepoints 
• Cancer patients receiving 
treatment in a P1T had 
no significant changes in 
QOL or performance 
status after one course in 
a P1T 
• Patients not eligible for a 
P1T experienced a 
significant decline in 
overall QOL and 
performance status one 
month later 
Hi
gh
 
M
ed
iu
m
 
Meyers et al.41 / 
Simultaneous 
Care: A Model 
Approach to the 
Perceived Conflict 
Between 
Investigational 
Therapy and 
Palliative Care 
To describe the 
findings of a 
pilot study trial 
of the 
simultaneous 
delivery of 
investigational 
therapy and a 
structured 
program of 
supportive care 
44 patients 
enrolled in a 
phase I or II 
trial along with 
a supportive 
home care 
program, and 
20 patients 
enrolled in just 
a phase I or II 
trial  
• Quantitative 
intervention 
pilot study  
• QOL assessed 
with 
instrument at 
five timepoints  
• Monitored 
referral to 
hospice and 
chemotherapy 
cycles 
administered 
• P1Ts in patients with 
advanced cancer may not 
pay sufficient attention 
to QOL and supportive 
care issues 
• A statistically significant 
increase in referral to 
hospice, and mean 
length of stay in hospice, 
was seen in simultaneous 
care group compared to 
control group  
Hi
gh
 
M
ed
iu
m
 
Moore10 / 
A Need to Try 
Everything: Patient 
Participation tn 
Phase I Trials 
To describe 
patients’ 
perceptions of 
participating in 
P1Ts 
15 patients 
enrolled in 
any P1T 
within the 4-
month 
recruitment 
period 
• Qualitative, 
longitudinal 
study 
• In-depth semi-
structured 
interview and 
open-stem 
questionnaires 
completed at 
two timepoints 
• Major themes: need to 
try anything and 
everything at any cost, 
living with incurable 
cancer whilst still hoping 
for miracle cure, and 
receiving self-benefit 
while giving to future 
patients  
• Being in a P1T is 
meaningful by providing 
a supportive structure 
and enabling hope 
M
ed
iu
m
 
Hi
gh
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Rouanne et al.12 / 
Evaluation of 
Sexuality, Health-
Related Quality-of-
Life and 
Depression in 
Advanced Cancer 
Patients 
To evaluate 
health-related 
QOL, depression 
and sexual 
function in 
advanced cancer 
patients treated 
in a P1T with 
molecularly 
targeted agents 
63 patients 
enrolled in 
any P1T 
within the 4-
month 
recruitment 
period in 
2011 
• Quantitative. 
longitudinal 
study  
• Initial 
consultation 
• Questionnaires 
completed at 
two timepoints  
• Patients enrolled in 
molecularly targeted 
agent P1Ts preserved 
mental and physical 
activity, but sexual 
activity declined 
• Statistically significant 
difference was found 
between baseline and 1-
month assessments for 
physical health, but not 
for mental health, on 
QOL questionnaire 
Hi
gh
 
M
ed
iu
m
 
Stetz28 / 
Survival Work: The 
Experience of the 
Patient and the 
Spouse Involved in 
Experimental 
Treatment for 
Cancer 
To describe the 
experiences of 
patients and 
their spouses 
undergoing 
experimental 
therapy for 
advanced cancer 
Purposive 
sample of 24 
patients 
enrolled in an 
experimental 
trial during 
recruitment 
period 
• Qualitative, 
longitudinal, 
grounded 
theory study 
• Unstructured 
interviews at 
four timepoints 
• Primary psychosocial 
process of participants 
was survival work: the 
work of choosing life 
over death. 
• Three phases of survival 
work were identified: (1) 
engaging, (2) monitoring, 
and (3) carrying on. 
Hi
gh
 
M
ed
iu
m
 
Sun et al.108 / 
Feasibility of a 
Palliative Care 
Intervention for 
Cancer Patients in 
Phase I Clinical 
Trials 
To test the 
feasibility of a 
palliative care 
intervention 
administered 
concurrently to 
cancer patients 
receiving 
treatment in a 
P1T. 
14 patients 
who 
consented to 
participate in 
a P1T during 
the 
recruitment 
period  
• Pre-post 
quantitative 
intervention 
pilot study 
• Intervention 
included 
baseline 
assessment, 
care 
conference, 
and two 
tailored patient 
educational 
sessions 
• Quantitative 
instruments 
completed at 
three 
timepoints  
• Concurrent palliative 
care was feasible for 
cancer patients treated 
in Phase I clinical trial 
settings. 
• Results indicated that 
symptom distress, 
psychological distress, 
and QOL were somewhat 
stable over two months, 
which suggests that 
concurrent palliative care 
may have potential in 
preventing precipitous 
declines in QOL reported 
in other studies. 
M
ed
iu
m
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Wilson et al.43 / 
Enhancing Cancer 
Trial Management: 
An Intervention 
Study of the 
Impact of 
Providing 
Information, Trial 
Results and 
Support to 
Patients in Phase I 
And II Anti-Cancer 
Drug Trials 
To present the 
qualitative 
findings from a 
nurse-led 
strategy for 
improving the 
management of 
the conclusion of 
patients’ 
participation in 
P1Ts 
117 patients 
(n=59 
intervention, 
n=58 control 
group) 
enrolled in 
any P1T at 
two medical 
centers 
within a 36-
month 
recruitment 
period from 
2001-2004 
• Randomized, 
pre-post mixed 
methods 
intervention 
study  
• Nurse 
intervention 
included P1T 
exit interview, 
leaflet, and 
follow-up call 
• Quantitative 
instruments 
completed at 
two timepoints 
with in-depth 
interview at 
second 
timepoint 
• Patients in the 
intervention group 
expressed fewer fears of 
abandonment, 
appreciated feedback 
about the trial, expressed 
satisfaction with the exit 
interview, and derived a 
feeling of support from 
the follow-up telephone 
call M
ed
iu
m
 
M
ed
iu
m
 
Wooten et al.11 / 
A Qualitative 
Assessment of the 
Experience of 
Participating in a 
Cancer-Related 
Clinical Trial 
To explore the 
experiences of 
patients enrolled 
in a cancer-
related clinical 
treatment trial 
using a focus-
group 
methodology 
14 patients 
who 
completed 
any cancer 
clinical trial 
within the 
past six 
months; 
71.4% (n=10) 
were patients 
enrolled in 
P1Ts 
• Qualitative, 
pilot study 
• Participants 
took part in 
one of three 
focus groups  
• Three 
participants did 
not attend a 
focus group 
(two were 
individually 
interviewed 
and one wrote 
feedback) 
• Clinical trial participation 
is a positive experience, 
although there are 
practical and emotional 
burdens. 
• Trial participants may 
benefit from closer 
follow-up, assessment of 
support needs, and help 
in re-evaluating meaning 
of trial participation if 
initial hopes and 
expectations aren’t met. 
M
ed
iu
m
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Yoder et al.117 / 
Expectations and 
Experiences of 
Patients With 
Cancer 
Participating in 
Phase I Clinical 
Trials 
To describe the 
expectations and 
experiences of 
patients 
enrolling in P1Ts 
37 patients 
enrolled in 
any P1T 
during the 
recruitment 
period 
• Quantitative, 
longitudinal 
pilot study  
• Interviews 
conducted with 
structured 
questionnaires 
pre-and post- 
P1T 
participation 
• Patients’ expectations for 
increased family support 
were met; expectations 
were not met for 
decreased tumor size, 
decreased symptoms, 
increased physician 
communication, 
decreased 
hospitalization, and 
increased activity. 
Lo
w
 
M
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TABLE 2.4  SUMMARY OF RESULTS OF ARTICLE EVALUATIONS 
  Evaluation of Rigor  
  Low Medium High Totals 
Evaluation 
of 
Relevance 
Low 1 3 9 13 
Medium 4 11 14 29 
High 0 8 1 9 
 Totals 5 22 24 51 
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 This chapter presents the results of the quantitative, longitudinal pilot study 
examining treatment burden and quality of life impact of participation during 13 parent 
/ child dyads participation in a pediatric oncology early phase clinical trial.  
3.1 INTRODUCTION 
Early phase clinical trials (EPTs) are the first steps to test novel medical therapies 
in humans.1,2 The process of developing therapies involves a series of clinical trials in 
humans; after preclinical testing, therapies are tested in phase I, phase II and/or pilot, 
and phase III clinical trials in order to obtain sufficient evidence of the therapy’s safety 
and efficacy.134 For the purposes of this study, EPTs include phase I, phase II, and pilot 
trials of investigational therapies that are still under development and not yet approved 
by the United States Food and Drug Administration. The challenge with pediatric EPTs is 
that, due to the investigational nature of the therapies being tested, children can only 
participate in an EPT when standard therapies are considered ineffective. The median 
life expectancy of children with relapsed cancer enrolled in a phase I clinical trial is 
between just 3.6 – 6.4 months.2,39,40  
Treatment burden is defined as the physical, financial, time, psychosocial, and 
procedural demands that a treatment places on a patient and their family, as well as its 
impact on patient and family functioning.92-94 Treatment burden is a dynamic, 
multidimensional concept that fluctuates over time due to severity of the patient’s 
condition, development of toxicities, and adjustment to the treatment. Treatment 
burden is different from burden caused by other factors such as symptoms or disease, 
because it is based on treatment for the disease, and not on either the natural history or 
natural symptoms of the disease.93 In adult patients, treatment burden encompasses 
time lost from work and other activities.135 Although children may not work, their time 
lost is equally important and burdensome; they would also benefit from spending the 
time required for treatments with family and friends or carrying out their usual 
activities. Although research has yet to confirm this, experts hypothesize that for 
children with chronic illness, treatment demands such as injections, blood samples, and 
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dietary restrictions may be particularly burdensome and negatively impact children’s 
quality of life (QOL).95,135  
A better understanding of treatment burden in the context of EPTs may help 
healthcare professionals, patients, and parents to make more informed treatment 
decisions.94 Although adults’ participation in phase I clinical trials provides hope and a 
sense of purpose, there are also significant associated physical, emotional, and practical 
burdens.3,4,10,11 The research with adults is not generalizable to pediatric EPTs because 
children are reliant on parents as providers, caregivers, teachers, moral compasses, 
disciplinarians, and proxy decision-makers. Some experts suggest that EPTs burden 
children with additional medical procedures and toxicities, negatively impact QOL, limit 
palliation opportunities, and disrupt dying and bereavement processes.13,14 Recent 
evidence, however, has demonstrated that an active palliative care program can ensure 
that measures of end-of-life care (e.g., presence or timing of do not attempt resuscitation 
orders, hospice use or length of stay) are not impacted by enrollment in a phase I clinical 
trial.26 Although research on experiences of communication and decision-making during 
EPT consent processes has been conducted, knowledge is lacking regarding parent and 
child experiences of treatment burden and QOL while participating in an EPT. Therefore, 
the purposes of this pilot study were to assess the feasibility and preliminary results of 
having children with cancer and their parents complete measures of treatment burden 
and QOL concurrent with EPT participation.  
3.2 METHODS 
This was a descriptive, longitudinal, pilot study with data collected from parents 
and children. Institutional Research Board approval was obtained for this study prior to 
enrolling participants. All parents and children aged > 18 provided written 
documentation of informed consent; children 7 - 17 years of age provided verbal assent 
for participation. Recruitment occurred between June 2011 and May 2013. 
All recruitment occurred at a large, Midwestern pediatric medical center. 
Parents and children were approached to participate after confirmation of their 
eligibility with the attending oncologist. The recruitment goal was 20 parent and child 
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dyads. As this was a pilot study, the sample size was based on participants available (i.e. 
annual EPT enrollment projections at the pediatric medical center), rather than on 
statistical power.136,137 A 24-month maximum length was set on recruitment.  
Child inclusion criteria were: (1) age 2 to 25 years; (2) receipt of at least one 
therapy prior to the EPT (i.e., phase I, phase II, or pilot clinical trial); (3) consented to 
participate in an outpatient-based EPT for relapsed/refractory pediatric cancer; (4) EPT 
therapy did not include 131I-metaiodobenzylguanidine (131I-MIBG) or oncolytic 
virotherapy; (5) enrolled within 48 hours of first dose of EPT therapy; and (6) ability to 
communicate in English. Parent inclusion criteria were: (1) age > 18; (2) self-
identification as biological parent or legal guardian of child; and (3) fluency in English. 
Eligibility criteria were established to prospectively capture the full experience of 
participation in a classic EPT where therapy involves either oral or intravenous agent(s) 
administered on a regular schedule to a child with relapsed and/or refractory cancer. To 
capture as full a data set as possible, an extended range of child ages was included 
based on ages covered by the PedsQLTM modules. EPTs involving 131I-MIBG therapy and 
oncolytic virotherapy were excluded due to the unique requirements of these studies 
that necessitated prolonged isolation from support systems. The first 48 hours was 
selected to ensure that baseline data reflected experiences at the time the EPT started. 
3.2.a Procedures  
Children were followed for either eight weeks (if length of treatment course was 
four weeks) or nine weeks (if length of treatment course was three weeks) during the 
EPT. This variance was due to a desire to standardize the time on study, while ensuring 
that children completed this study at the end of an EPT course. Assessments were 
completed at baseline, post-first disease evaluation, and end of this study. The baseline 
assessment was completed after the child was enrolled in the clinical trial, preferably 
before treatment started, but no more than 48 hours after the administration of the 
first dose of the investigational therapy. The post-disease evaluation assessment was 
completed after the first disease evaluation was performed, but no more than 7 days 
after the child/family were provided the results of the disease evaluation. The off-study 
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assessment was completed at the end of a course, after the child had been on the EPT 
for 60 (+/- 5) days. In addition, parents were asked to complete the Diary of Trial 
Experiences on an ongoing basis (i.e. two to three times a week) at home. To ensure 
completeness, a study team member reviewed diary entries with the parent every 5 to 
14 days throughout the study. Table 3.1 provides a list of measures completed with 
each assessment, and by which participants. Participants received $25 in cash upon 
completion of the baseline and post-disease evaluation assessments, and $50 in cash 
after completing the off-study assessment. 
3.2.b Measures 
3.2.b.1 Family Demographics  
Parents completed an investigator-designed Family and Patient Demographic 
form at the baseline assessment. In addition to standard demographics, data included 
family composition, type of central line access, whether central line access was placed 
specifically for the EPT, and distance from primary household to pediatric medical 
center in miles and minutes of travel time.  
3.2.b.2 Child Performance Status  
The child’s Lansky or Karnofsky scale scores were evaluated at each assessment 
by a member of the health care team and documented in the clinical trial record. These 
scales are similar with the Lansky scale applicable for children less than 16 years of age 
and the Karnofsky for those aged 16 years and older. Both scales (1) quantify cancer 
patients' general well-being and activities of daily life, (2) have well-established 
reliability and validity, (3) are responsive to change, (4) are widely used, and (5) use a 
single score of 0 to 100 in increments of 10, where 0 is death and 100 is normal health 
with no complaints.97-99  
3.2.b.3 EPT Data  
Using an investigator-designed form, the study team extracted data from the EPT 
protocol, consent form, and the child’s EPT records. Data captured included: length of 
treatment course; frequency, number and duration of required and optional blood 
draws, physical exams, imaging, bone marrows, lumbar punctures, clinic visits and 
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infusions; number of planned separate visits to a medical facility / laboratory; number of 
expected separate needle punctures; optional observations that the child / parent 
agreed to provide for the EPT (e.g. pharmacokinetic and pharmacogenetic samples); and 
outcomes of EPT disease evaluations. 
3.2.b.4 Treatment Burden  
Based on an adaptation of the Collection of Indirect and Non-medical direct 
costs (COIN) form,46 the study team created the Diary of Trial Experiences to capture the 
treatment burden associated with EPT participation for parents and children. The COIN 
form was a feasible and practical method for assessing patient cost data in a study of 29 
adult cancer patients being treated for prostate carcinoma.46 Adaptations included 
reformatting and capturing time spent in different activities; financial costs associated 
with child care, lodging, and meals; venipunctures; and reasons why usual activities 
were missed. The additions were made by adding columns and rows as needed into the 
tables structuring the form, and by adding a separate section at the bottom of a page to 
capture venipunctures. The Diary of Trial Experiences was completed by parents on an 
ongoing basis and used to directly capture the number of appointments and activities 
related to the EPT, including time spent on and financial cost of those activities. See 
Table 3.2 for a listing of elements included in the diary.  
3.2.b.5 QOL  
The standardized and widely used PedsQLTM modules were used to assess QOL, 
including: the PedsQLTM Quality of Life Inventories (Standard Version), Cancer Modules, 
and Family Impact Module. The 21-to 23-item Quality of Life Inventories measure 
health-related QOL in children and adolescents, with subscales for physical, emotional, 
social, and school functioning. The 25- to 27-item Cancer Modules measure elements of 
health-related QOL specific for children and adolescents with cancer, with subscales for 
pain and hurt, nausea, procedural anxiety, treatment anxiety, worry, cognitive 
problems, perceived physical appearance, and communication. The 36-item Family 
Impact Module measures parent physical, emotional, social, and cognitive functioning; 
communication; worry; family daily activities; and family relationships. For all modules, 
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5-point response options range from ‘Never’ (100) to ‘Almost Always’ (0). The Likert 
scores were then transformed to a 0-100 scale; as the items in PedsQLTM modules relate 
to problems, higher scores indicate better QOL and less problems. The total score for 
each module was determined by averaging the sum of all the scores for the items 
answered. A change of between 4.4 to 4.5 in the total score is the standard for a 
minimal clinically important difference in the PedsQLTM Quality of Life Inventories.48 
Advantages to the PedsQLTM modules are their ease of completion, demonstrated 
internal consistency and reliability, and established responsiveness to change when 
repeatedly administered in short intervals.47-53 For most children in this study (based on 
child’s age), both parent report and child self-report versions of the PedsQLTM Quality of 
Life Inventories and Cancer Modules were available, allowing parent and child to 
separately complete these modules. The parent completed the Family Impact Module. 
3.2.c Statistical Analyses  
All data were analyzed using descriptive statistics. Since children were enrolled 
in EPTs with varying course lengths, treatment burden per week was calculated for each 
participant as the sum of entries in the Diary of Trial Experiences for course 1 of the EPT 
divided by the number of weeks per course. Descriptive statistics of treatment burden 
per week were then calculated.  
Feasibility was assessed by the following criteria: (1) > 75% enrollment of all 
eligible parent and child dyads; (2) > 80% retention of participants at the post-disease 
evaluation assessment; (3) > 90% of questions answered by parents and children on 
each measure. Retention was evaluated as the rate of completion of the post-disease 
evaluation assessment by the 13 dyads who enrolled in the study, as completion of one 
course in the EPT was considered the minimum to be evaluable for this study. The same 
instruments were completed at the post-disease evaluation and off-study assessments, 
so selecting the post-disease evaluation provided a full set of data to be compared with 
the baseline assessment and ensured that the experiences of children who were only in 
the EPT for one course were captured. 
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3.3 RESULTS 
3.3.a Family Demographics, Child Performance Status, and EPT Data  
The accrued sample consisted of 13 parent and child dyads. The children were 
mostly female (69.2%) and white (76.9% white, 15.4% black, 7.7% other). The mean age 
of the children was 11.4 years old (SD=4.9, range 4-20) and the mean number of 
children in the household was 1.8 (SD=1.2, range 0-4). More than half of the children 
had some sort of central venous access in place (Port 38.5%, PICC 15.4%). Parents’ 
annual income levels were fairly evenly distributed across categories (<$20,000 15.4%; 
$20-$40,000 23.1%; $40-$60,000 23.1%; $60-100,000 23.1%; >$100,000 15.4%), and the 
majority of parents had attended college or had a professional degree (93.3%). Mean 
distance of the primary household from the medical center was 78.8 miles (SD=96.0, 
range 2-300) or 80.8 minutes (SD=70.6, range 15-240). The median baseline 
performance score of the children was 90 (SD=9.0, range 70-100). The children were 
participating on five different EPT protocols. See Table 3.3 for descriptive statistics 
summarizing requirements across the five EPT protocols.  
3.3.b Aim 1: Feasibility 
3.3.b.1 Enrollment of Eligible Parent and Child Dyads.  
As shown in Figure 3.1, of the parents and children approached to participate (n 
= 15), only one parent and child dyad declined to participate (92.9% participation rate). 
However, one child was determined to be ineligible following consent due to 
communication difficulties resulting from a brain tumor, resulting in final enrollment of 
13 of the 15 dyads approached to participate (86.7% enrollment rate). Both percentages 
were above the criteria of >75% enrollment, indicating that recruitment to this pilot 
study met feasibility criteria. 
3.3.b.2 Retention of Eligible Parent and Child Dyads.  
Per Figure 3.1, three children (23.1%) deteriorated due to disease progression or 
suffered sufficient toxicities to be withdrawn from the EPT prior to their first disease 
evaluation. Thus, the criteria of 80% of study participants remaining on this study and 
completing the post-disease evaluation assessment was not quite met (76.9% retention 
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was achieved at this time point). Overall, only seven children (53.8% completion rate) 
remained on this study at the off-study assessment conducted 60 (+/- 5) days after 
enrollment, although no parent and child dyads were lost from this study for reasons 
other than the child’s removal from the associated EPT.  
3.3.b.3 Completion of Measures.  
Each review of the Diary of Trial Experiences with the parent required between 5 
– 15 minutes to complete. The reviews were either done while the parent was waiting 
at the medical center, or a study team member contacted the parent over the 
telephone. The Diary of Trial Experiences was too complicated to be completed by most 
participants without some assistance. Thus, rather than completing the diary at home 
on an ongoing basis, most parents waited and completed the form during a review with 
the study team member. Some questions on the diary were either too uncomfortable or 
too difficult for most participants to answer, and many participants elected to not 
provide that information. See Table 3.2 for a listing of elements of the diary that were 
observed by study team members to be easier and more difficult to answer. Overall, the 
feasibility criteria of 90% of the Diary of Trial Experiences being successfully completed 
before the review with a study team member was not met. 
QOL measures were generally all completed, with only two individual child 
PedsQLTM modules missed during an assessment due to study team errors. The baseline 
assessment required between 20 – 40 minutes to complete, and was usually completed 
at the medical center either prior to or during an appointment (in a waiting room, clinic 
appointment room, or in their own room while inpatient). Two parents elected to 
complete their baseline PedsQL™ modules at home and return them at the next visit. 
The post-disease evaluation and off-study assessments required between 15 – 30 
minutes to complete and all were done while the parent and child were waiting at the 
medical center.  
There was minimal missing data from both parents and children on individual 
PedsQL™ modules. One parent did not respond to any of the five questions in the 
PedsQLTM Quality of Life Inventory related to school functioning (78.3% completion of 
 53 
that module) and two questions related to treatment anxiety on a PedsQLTM Cancer 
Module (92.6% completion). In addition, three other parents did not respond to one 
question in an individual PedsQL™ module (95.6 – 96.3% completion). Three different 
children did not answer one of the questions in one PedsQL™ module (95.6 – 96.3% 
completion). One child did not respond to five questions related to social functioning on 
a PedsQLTM Quality of Life Inventory (78.3% completion of that module). Overall, the 
children completed 99.4% of the questions on 52 individual PedsQLTM modules they 
were provided to complete, while the parents completed 99.5% of the questions on 87 
modules. There were no detectable patterns to the questions not answered. However, 
many parents and children were observed by study team members as having difficulty 
answering questions related to school, particularly since many children were not 
attending school due to the advanced stage of their cancer and the PedsQL™ modules 
do not provide ‘Not Applicable’ as a response option. Thus, the school functioning 
subscale of the PedsQL™ Quality of Life Inventories likely resulted in inconsistent data. 
Overall, the feasibility criteria of 90% of the questions answered on each measure by 
parents and children was met.  
3.3.c Aim 2: Preliminary Results  
3.3.c.1 Treatment Burden.  
Table 3.4 provides the descriptive statistics of per week treatment burden for 
parent and child dyads who completed the post disease evaluation assessment (n=10). 
Median data suggest that at least half of the children had an average of 3.8 
appointments per week, requiring an average of 11.5 hours of time and 2.8 needle 
punctures per week, and resulting in an average of 9.9 hours of missed activities and 
$10.60 in out of pocket costs per week. Appointment hours included overnight 
admissions for observation experienced by 70% of the children for their first dose of EPT 
therapy. These overnight admissions were for monitoring and collection of timed 
pharmacokinetic laboratory specimens and were considered as one 24-hour long 
appointment. Children’s missed activities included school, attending camp, and family 
activities, and were almost entirely due to EPT appointments, with only three children 
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missing activities due to not feeling well. 
3.3.c.2 QOL.  
Figure 3.2A shows mean child and parent PedsQLTM Quality of Life Inventories 
scores at each assessment. While emotional health scores reported by both parents and 
children increased over time, other scores did not follow a continuous pattern. In 
general, children self-reported higher QOL scores than their parents reported on their 
behalf. The exception to this was the physical health summary score at post-disease 
evaluation and the psychosocial health summary score at baseline, which the parents 
generally reported as higher than their child. Statistical comparison could not be 
performed due to the small sample size. 
Figure 3.2B shows mean child and parent Cancer Modules scores at each 
assessment. While the total scores reported by both parents and children increased 
over time, patterns of change for the other subscales varied over time. A wide variation 
between parent and child reports occurred for the communication subscale at both 
baseline and post-disease evaluation, with children self-reporting much lower scores 
than their parents on their behalf. Children generally reported higher procedural anxiety 
subscale scores than parents did at all time points, but particularly for the post-disease 
evaluation assessment; higher procedural anxiety subscale scores indicate less anxiety 
associated with needle sticks and other procedures performed as part of the child’s 
cancer care. Again, statistical analyses were not performed due to the small sample size.   
Figure 3.2C shows the mean Family Impact Module scores as reported by 
parents at each assessment. Patterns of change on the worry and communication 
subscales varied over time, while the remaining scores continuously improved through 
the EPT. The overall total scores on this module were stable but low at all time points, 
indicating that the child’s cancer had a significant impact on the family. In particular, 
parents reported notably lower scores on the worry subscale, indicating that parents 
were very worried about their child’s cancer.  
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3.4 DISCUSSION 
  The first major finding of this pilot study was that feasibility was not clearly 
established. While the goal of > 75% enrollment was met, the goals for recruitment and 
retention were not met. In particular, the overall recruitment goal of 20 dyads was not 
achieved despite recruiting over a 24-month period. Challenges to recruitment included 
a slow accrual to non-131I-MIBG and oncolytic virotherapy EPTs and lack of sufficient 
study team members to approach all potential participants.  
The primary retention challenge was that attrition was higher than expected; 
although the goal of > 80% retention was not quite met, no participants opted to leave 
this study early. All attrition was due to the child’s removal from the EPT due to either 
toxicity or disease progression. While this was an anticipated problem, given the limited 
life expectancy of children with cancer enrolled in EPTs, feasibility was impacted by this 
attrition 2,39,40. An important implication for future research with this population is to 
ensure that data is captured at multiple time points, starting before the end of the first 
course of therapy in the EPT, to ensure that attrition does not prohibit capturing the 
experiences of participants who are unable to remain in the EPT.  
In terms of measure completion, the goal of > 90% of questions being answered 
on each measure was met for the PedsQLTM measures, but not for the Diary of Trial 
Experiences. This diary proved to be overly complicated to complete without the 
assistance of a study team member. While treatment burden data were captured using 
the diary, it is clear that revisions to both the format and content are needed to 
enhance the diary’s usability and acceptability.  
 To improve feasibility, the following suggestions are recommended for future studies. 
First, to maximize recruitment efforts and minimize bias in those approached to 
participate, recruitment should clearly and systematically be tasked to multiple study 
team members. In addition, future research should be conducted at multiple sites or 
within a cooperative group to enhance recruitment and generalizability of findings. 
Lastly, the format of the Diary of Trial Experiences should be revised to mimic EPT 
medication diaries (i.e. one diary per course of therapy, with one line in the diary to be 
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completed each day of the course).  
The second major finding was that while some interesting insights were provided 
by completion of the PedsQLTM modules, it is less clear that the Diary of Trial 
Experiences has sufficient value to be worth pursuing in future research. While it may be 
useful to obtain quantitative results regarding EPT treatment burden, in its current form 
this diary only measures objective elements of treatment burden (i.e. number of 
medications, number of appointments, and time at appointments). The subjective 
elements of treatment burden, including the different perceptions patients and their 
family have of a treatment’s burden, are not captured. These perceptions include 
intangible elements that significantly impact the experience of treatment burden, such 
as difficulty administering oral medications to a young child, the meaning attributed to 
side-effects of the treatment, and beliefs about a treatment’s effectiveness.93 
Qualitative research would be needed to identify subjective elements for inclusion. For 
the Diary of Trial Experiences to be valuable, it should be able to identify children or 
families who would benefit from further support or allow families to specify their need 
for further support. However, in its current format this diary does not seem to perform 
any better than standard psychosocial assessments already being done by social 
workers and other health care providers.  
The third major finding was that preliminary results suggest there is value in 
having parents and children complete QOL measures during EPT participation. Although 
the PedsQLTM measures have been widely used in a variety of settings, no evidence was 
found of their use in early phase pediatric oncology clinical trials, prior to this study. In 
particular, having both parents and children separately complete the PedsQLTM 
modules, provided insight that there may be time points when parents’ and children’s 
perceptions of indicators of the child’s quality of life may substantively differ. An 
example of this is the wide variation between parent and child reports on the PedsQLTM 
Cancer module communication subscale at baseline and post-disease evaluation, which 
suggests that children may have had more difficulty communicating concerns related to 
their cancer at these times than their parents were aware of. This discord between child 
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and parent reports has been acknowledged as prevalent whenever a concern is not 
directly observable (e.g. when asking about pain, communication, and personal 
experiences).138,139 In this population, it is unlikely that the school functioning subscale 
of the PedsQL™ Quality of Life Inventories will produce valid results since many children 
participating in EPTs do not regularly attend school and ‘Not Applicable’ is not a 
response option. In a study of the QOL of children with advanced cancer, Deborah 
Tomlinson, Hinds, Bartels, Hendershot, and Sung140 also reported significant missing 
data for the school functioning subscale. A larger study of the use of QOL measures 
during EPT participation is necessary to better elucidate the value they provide. In 
future research, to more fully understand the impact of EPT participation on physical 
health, it would be helpful to capture occurrence of toxicities along with completion of 
QOL measures. The use of PROMIS Pediatric measures (i.e. Physical Functioning - 
Mobility, Physical Functioning - Upper Extremity, Pain Interference, Fatigue, Depression, 
Anxiety, and Peer Relationships) should also be considered in future research.141  
An additional result was that all participants in this study reported minimal 
financial burden directly associated with EPT participation. In particular, the reported 
financial burden was not grossly observed to correlate with other data, such as distance 
traveled. In contrast, for adults with chronic illness financial burden has emerged as the 
most problematic element of treatment burden.94 Potential explanations for this finding 
include: (1) Parents were unwilling to report monetary burdens; (2) Parents were unable 
to accurately track monetary burdens; (3) Strong levels of financial support were offered 
by the pediatric medical center through foundations that support families of children 
with cancer; and, (4) Baseline socioeconomic demographic characteristics of parents 
and children enrolling in a pediatric oncology EPT may differ from the general 
population of adults with chronic illness.  
The results of this pilot study are limited by small sample size, use of a single site 
for recruitment, the wide inclusion age range resulting in participants aged 4 to 20 
years, and attrition of study participants. In particular, only a preliminary presentation 
of QOL results was possible. A problem affecting all studies of this population, including 
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ours, is that the interpretation of results is hampered by the bias created by participant 
attrition. Children with the most toxicities and disease progression do not remain on 
study to complete follow-up assessments.  
3.5 CONCLUSIONS 
This avenue of research is important, and likely to be feasible if conducted at 
multiple sites or within a cooperative group. To date, no studies have considered the 
impact of EPT participation, in terms of burden and QOL impact, on children with cancer 
and their families. Instead, current research focuses on how QOL is impacted by the 
child’s current health status; the impact of treatment burden on QOL has not yet been 
considered. While it is unclear whether the Diary of Trial Experiences, as an objective 
measure of treatment burden, is worthy of further research, this pilot study highlights 
that measures of QOL impact of EPT participation can feasibly be completed by children 
with cancer who are participating in an EPT and their parents, and may provide valuable 
insights that could guide personalized interventions.  
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FIGURE 3.1  STUDY RECRUITMENT AND RETENTION 
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Figure 3.2  Mean PedsQL Scores at Each Assessment 
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TABLE 3.1  INSTRUMENTS COMPLETED BY PARTICIPANTS AT EACH ASSESSMENT 
Instrument Baseline Assessment 
Post Disease 
Evaluation 
Assessment 
Off-Study 
Assessment 
Child and Family 
Demographics Form Parent ---------- ---------- 
Diary of Trial 
Experiences Completed Throughout Study by Parent 
PedsQLTM Quality of 
Life Inventories 
Parent and 
Child Parent and Child Parent and Child 
PedsQLTM Cancer 
Modules 
Parent and 
Child Parent and Child Parent and Child 
PedsQLTM Family 
Impact Module Parent Parent Parent 
 
 
  
 62 
TABLE 3.2  ELEMENTS FROM THE DIARY OF TREATMENT EXPERIENCES 
Easily Answered Difficult to Answer 
• Type of services child used (e.g. 
oncology clinic, family doctor, 
emergency room, imaging, lab draw, 
parking, lodging, meals, and child care) 
• Number of times services used 
• Amount of time spent at medical 
service visits 
• Out of pocket costs associated with 
medical services, parking and lodging 
• Number of venipunctures, finger sticks, 
port access, and central line accesses 
• Type of activities child missed 
• Amount of time child missed at 
activities 
• Reason activities were missed by child 
or parent 
• Out of pocket costs associated with 
transportation, child care, and 
meals 
• Type of activities parent missed 
• Amount of time parent missed at 
activities 
• Estimated loss of pay due to 
activities parent missed 
• Insurance coverage for medical 
services and other services 
• Other financial coverage for 
medical services and other services 
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TABLE 3.3  SUMMARY OF TOTAL EPT COURSE 1 PROTOCOL REQUIREMENTS* 
Item  Median Mean SD Range 
Length of Course (weeks) 4 3.8 0.4 3 - 4 
Baseline Imaging (number of scans) 2.5 2.8 1.2 2 - 5 
Physical Exams (number) 4 3.8 0.4 3 - 4 
Required Blood Draws (number) 12 11.3 4.7 4 - 16 
Optional Blood Draws (number) 2.5 1.8 1.5 0 - 3 
End of Course Imaging (number of 
scans) 
2 1.5 1.2 0 - 3 
Total Required Observations 20.5 19 5.9 10 - 26 
 
*n=5 different EPT protocols 
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TABLE 3.4  DESCRIPTIVE STATISTICS FOR TREATMENT BURDEN PER WEEK 
DOCUMENTED* 
Treatment Burden Per Week Median Mean SD Range 
Number of Appointments  3.8 3.4 0.8 2.3 – 4.3 
Time for Appointments (hours) 11.5 11.6 2.7 7.9 – 17.8 
Activities Child Missed (hours) 9.9 15.6 13.2 2.3 – 37.5 
Out of Pocket Cost ($) 10.6 15.6 16.5 0 - 50 
Number of Needle Punctures 2.8 2.7 1 0.5 – 4.3 
 
Note. Children were enrolled in EPTs with varying course lengths. Per week treatment 
burden was calculated for each participant as the total of entries in the Diary of Trial 
Experiences for course 1 of the EPT, divided by the number of weeks.  
 
* n = 10 parent and child dyads completing the post-disease evaluation assessment 
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 This chapter presents the results of the phenomenological study examining 11 
parents’ experiences when their child with cancer participated in a P1T.  
4.1 INTRODUCTION 
Cancer persists as the second most common cause of death (after accidents) for 
children aged 1 to 14 years, and the incidence of cancer in children and adolescents is 
continuing to increase.29,30 However, survival rates for childhood cancers are improving; 
between 1975 and 2011 overall five-year survival rates for childhood cancer improved 
by over 43% (to 83%).29,30 These improvements in childhood cancer outcomes are 
attributed to better therapies and high levels of participation in clinical trials.142,143 
Phase I clinical trials (P1Ts) are the critical first stage of clinical trials, and involve 
determining the recommend dosage and testing the safety of new therapies.1,2,33,143 
P1Ts are necessary for developing new therapies that will improve outcomes for 
children with cancer. 
The Declaration of Helsinki requires that “the interests of the [research] subject 
must prevail over the interests of science and society”.44 The ethical conflict inherent in 
pediatric oncology P1Ts is that the primary aims of these trials are not intended to 
provide direct benefit to participants. Due to the investigational nature of the new 
therapies being tested, children are only eligible to participate in P1Ts when their cancer 
is considered incurable.18,39,74 The median life expectancy of children with relapsed 
cancer enrolled in a P1T is less than seven months.2,39,40 Despite this, clinicians and 
parents pursue P1Ts for children with cancer based on hope that the investigational 
therapy being tested will improve the child’s disease prognosis.17,18,25,74,143 To address 
the ethical concerns of pediatric oncology P1Ts, it is important to understand the 
experiences of participants in these trials. Experiences with P1Ts may vary widely given 
the toxicities of the P1T therapy, distance travelled to the P1T center, previous 
relationship with the P1T medical team, response of the child’s cancer to the P1T 
therapy, and previous clinical trial experiences. However, research has not been 
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performed on the benefits, burdens, or impact of P1T participation for children with 
cancer or their parents outside of the process of consenting to the P1T.17-26,144  
The purpose of this study was to identify the fundamental commonalities and 
meaning of the experience of P1T participation from the perspective of parents of 
children with cancer. A descriptive, cross-sectional, empirical phenomenological study 
was conducted using an adapted version of Colaizzi’s method.54 Phenomenological 
research is used to describe the essence (i.e. the fundamental commonalities and 
meaning without which a phenomenon would not be what it is) of the lived experiences 
of people in similar life situations.55-58 The specific aim was to develop a rich, in-depth, 
phenomenological description of parents’ lived experiences of having a child with cancer 
participate in a P1T. 
4.2 METHODS 
This study was approved by the Indiana University Institutional Review Board.  
4.2.a Setting 
Parent recruitment occurred at two time points. First, a pilot interview was 
conducted with one parent recruited by the primary researcher, based on prior 
knowledge of the parent’s advocacy efforts. The main study then recruited participants 
from two pediatric academic medical centers in the Midwest United States that conduct 
pediatric oncology P1Ts. Parents were also recruited for the main study from national 
childhood cancer support and advocacy groups that were not affiliated with either 
medical center.  
4.2.b Sample 
The purposive sample consisted of parents of children with cancer who 
participated in a P1T. Sample size in phenomenological studies is not determined in 
advance. Rather, sampling continues until data analysis yields thematic redundancy, and 
generally ranges between 10 and 20 participants.64,145-149 No effort was made to control 
for demographic variables or clinical history since empirical phenomenology is used to 
describe the commonalities of experiences, even within a diverse sample.54,150,151 Efforts 
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were made to ensure the sample included parents of children with cancer who had a 
diverse range of positive and negative outcomes following the P1T. 
Parent was defined as anyone who served in the role of primary caregiver (e.g. 
biological parent, guardian, grandparent). Up to two parents were interviewed for each 
eligible child. Parent inclusion criteria were: (1) age > 18; (2) self-identification as 
primary caregiver of child; (3) fluency in English; and (4) having provided consent for 
child’s P1T participation. In addition, the parent’s child must have been: (1) enrolled in 
at least one pediatric oncology P1T in the United States; (2) aged < 18 during the P1T; 
and (3) removed from the P1T at least 60 days prior (to ensure that the off-study 
transition had fully been experienced). Parents were ineligible if the child had died 
within the previous 60 days.  
4.2.c Recruitment 
Institutional Research Board approval was obtained prior to screening or 
enrolling participants. Recruitment occurred between March and December 2016.  
Parents were recruited at one medical center by the primary researcher and at 
the second medical center by experienced pediatric oncology clinical research 
professionals. Parents were pre-screened for eligibility by reviewing all participants 
enrolled in a P1T within the past four years. Potentially eligible participants were 
recruited using the method developed for research involving parents of deceased 
children.68 Specifically, a recruitment-letter was sent from the phase I center with 
instructions for enrolling as well as opting out of further contact attempts. After a two-
week waiting period, potential participants were contacted via telephone.  
Parents were also recruited from cancer support and advocacy groups by the 
primary researcher. The primary researcher contacted key leaders of the groups who, if 
they approved, released information about the study to members (i.e. recruitment 
materials including a link to a Facebook page). Potentially eligible parents then 
responded if interested in participating.  
Parents who responded to a recruitment attempt completed the screening 
process and were given additional information about the study by the study team 
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member who recruited them. After confirming participants’ interest and eligibility, a link 
was sent to an online Research Electronic Data Capture (REDCapTM) survey152 via 
electronic mail that allowed participants to formally agree to participate and begin study 
procedures. If desired, participants could complete the agreement to participate and 
other REDCapTM surveys in writing. 
4.2.d Procedures 
Parents who agreed to participate completed the demographic form and 
provided their interview availability through REDCapTM. The interview date and time was 
agreed upon between the participant and the primary researcher. The primary 
researcher sent the interview question via email at least one day in advance of the 
interview.68 Interviews were audio-recorded and done over the telephone by the 
primary researcher at a time convenient to the parent. Seven to fourteen days after the 
interview, a follow-up call was made by another researcher to clarify any ambiguous 
details from the interview and to ensure no undue distress resulted from participation 
in this study. Lastly, the researcher who recruited each participant manually extracted 
data from the child’s clinical trial record into the REDCapTM database. Completion of 
study-related procedures was monitored on a weekly basis by the primary researcher 
and when needed follow-up reminder emails were sent to participants. Participants 
received a $50 gift card at the end of the study in recognition of their time and effort. 
4.2.d.1 Demographic form 
Participants electronically completed a demographic form via a REDCapTM 
survey. Questions included: child’s age at P1T enrollment, gender, race, ethnicity, type 
of cancer, education level, and school attendance at time of enrollment in the P1T; 
family configuration; household income; parent education level; living arrangements; 
distance to the P1T center; and details surrounding transitions on and off the P1T.  
4.2.d.2 Phenomenological interview 
The goal of empirical phenomenological interviews is to obtain clear, rich 
descriptions of participants’ experiences.149,153 Of particular importance is ensuring that 
the participant describes their experiences without analysis or interpretation, using a 
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small number of broad, open-ended questions.54,56,58,149,153,154 For this study, one broad 
data-generating question was asked :  
I am interested in hearing what it was like when [child’s name] was 
enrolled in [that study/those studies]. I would like to hear as much about 
the experience as you can remember, including all the circumstances, 
perceptions, and conversations during [child’s name]’s time in the phase I 
[study/studies]. It is sometimes helpful to begin telling what it was like as 
a story, starting when you first learned about the phase I [study/studies] 
through to the time [child’s name] was taken off the [study/studies].  
To ensure that the parent guided the discussion, there was no set agenda of 
topics to cover.148,153 Probes such as: "Please tell me more about that" and "What did 
that mean to you?" were used to enhance depth of the discussion.148,153 After parents 
finished fully describing their experiences, if any of the following were not mentioned, 
the interviewer asked the parent for elaboration: learning about and enrolling their child 
on each P1T, receiving the first dose of each P1T therapy, and transitioning off each P1T. 
Lastly, the parent was asked if they had any advice for parents considering enrolling 
their child in a P1T, and if there were any other important events or people who 
impacted their P1T experience.  
4.2.d.3 Clinical trial data extraction 
After the phenomenological interview and follow-up call were completed, 
selected information was retrieved from the child’s clinical trial record and entered into 
the REDCapTM database by the researcher who recruited each participant.  This 
information included: type of trial, investigational therapy and its method of 
administration, concomitant medications, eating or drinking restrictions, required and 
optional observations included in the trial, toxicities and serious adverse events the 
child experienced, length of time on the trial, reason for removal from the trial, and 
results of disease evaluations. 
4.2.e Data Analysis 
Interviews were audio-recorded and professionally transcribed by a contracted, 
Health Information Portability and Accountability Act (HIPAA)-approved provider. The 
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primary researcher de-identified and verified the accuracy of the transcripts, prior to 
beginning data analysis. Data were managed using NVivo™ software.  
Steps of analysis, per the adapted Colaizzi method, included:54 (1) repeated 
readings of the full interview transcript for a sense of the whole; (2) identification of 
substantive phrases; (3) restatement of substantive phrases in general terms; (4) 
formulation of derived statement meanings; (5) development of themes and 
organization of themes into theme clusters and categories; (6) generation of an 
exhaustive description of the experience; and (7) development of the essential structure 
of parents’ experiences of having a child enrolled in a P1T. Table 4.1 provides examples 
of steps 2 through 4.  
Data analysis occurred simultaneously with participant recruitment. Thematic 
redundancy was established when new themes no longer emerged from interview 
transcripts. After achieving thematic redundancy, two additional participants were 
recruited to confirm that no potential themes were left unidentified. The demographic 
form and clinical trial record were used to describe the sample, understand details 
specific to the P1T in which the child was enrolled, inform parents’ descriptions of their 
experiences, and provide context for interpreting experiences. In addition, when more 
than one parent participated, the consistency and divergence of their narratives and 
themes was explored as part of determining the essence of the phenomenon. 
Crucial elements of the empirical phenomenology method that were used 
included a phenomenological attitude adopted through bracketing and avoiding 
premature closure to the phenomenon, and imaginative variation to determine the 
essence of the phenomenon.58,65,155-159 Prior to beginning this study, the primary 
researcher reflected in writing on personal and theoretical knowledge of the P1T 
experience. These reflections were used to recognize when the phenomenological 
attitude had been compromised. In addition, a reflexive diary of decision-making and 
theme emergence was kept throughout interviewing and data analysis.66 Lastly, the 
dissertation chair reviewed the first nine interview transcripts and weekly or bi-weekly 
assisted with data analysis to ensure that the phenomenological attitude was 
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maintained and that each step of the process was performed through discussion and 
consensus.  
After data analysis was complete, two clinicians validated the findings. The 
primary researcher sent the exhaustive description and essential structure to an 
experienced phase I physician and nurse who were asked to answer the following. (1)  
What ways do these findings ring true? (2) What ways do they not ring true? (3) How 
could these findings be useful in the design or conduct of pediatric oncology P1Ts? 
Although no substantive changes were made based on feedback provided, some 
concepts and ideas in the exhaustive description were clarified through their feedback.  
4.3 FINDINGS 
4.3.a Description of Sample 
The accrued sample consisted of 12 parents. Nine parents (75.0%) were 
recruited from pediatric medical centers, two parents (16.7%) from childhood cancer 
groups, and one parent (8.3%) who completed the pilot interview . The response rate at 
Medical Center 1 was 35.3% (6 of 17 parents of children with cancer approached to 
participate enrolled in this study); the response rate at Medical Center 2 was 33.3% (3 of 
9 approached). All eligible parents (100%, n=2) recruited through childhood cancer 
groups chose to enroll. Of the parents enrolled, one parent from Medical Center 1 
completed the consent and demographic forms but did not follow through and 
complete the interview, resulting in an evaluable sample of 11 parents (91.7% retention 
rate). Mean interview length was 59.1 minutes (SD=15.1, range 29.9-85.3 minutes).  
Parents were mostly female (81.8%, n=2 males) and white (100%) with non-
Hispanic ethnicity (90.9%; one parent did not specify ethnicity). The mean age of the 
children with cancer was 11.2 years (SD=5.2, range 3-17) at enrollment to the first P1T. 
Parents reported their annual household income as $40-$59,999 (27.3%); $60-99,999 
(18.2%); >$100,000 (36.4%); Don’t Know (18.2%). No parent reported an annual income 
of <$40,000 per year. Most parents had at least some college or professional degree 
(81.8%). Parents’ reports of the distance they traveled from their household to the P1T 
center varied between: 10 to 29 miles (36.4%), 30 to 89 miles (18.2%), 90 to 239 miles 
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(27.3%), and greater than 240 miles (18.2%). 63.6% of parents were bereaved (n=7), 
18.2% of parents had a surviving child who was still receiving treatment (n=2), and 
18.2% of parents had a child who was a long term survivor and off treatment (n=2). Only 
two parents enrolled were a couple; all other participants were parents of different 
children. The children participated in a total of 15 P1Ts, with a mean of 1.6 P1Ts per 
child (range 1 - 3; median 1). The number of grade 2 or greater toxicities that the 
children experienced during a P1T varied from 2 to 15 (median 7, mean 7.9, SD 4.7). The 
maximum toxicity grade experienced by the children during a P1T ranged from grade 2 
to grade 5 (median grade 3). Although racial, ethnic, and social diversity was lacking in 
the sample, a strong diversity in P1T experiences was captured. P1T experiences 
included: being removed early in the first course of a P1T, participating in multiple P1Ts, 
dying unexpectedly during a P1T, achieving a full remission from P1T therapy, and 
actively participating / considering participating in another P1T. See Table 4.2 for further 
characteristics of the sample and their P1T experiences. 
4.3.b Theme Categories 
Data analysis identified five main theme categories. Theme categories abstracted 
were: (1) being the parent of a child with high-risk cancer; (2) contending with high-risk 
cancer; (3) perceptions of their child’s experiences; (4) the nature of P1T participation; 
and (5) remembering and forgetting. See Table 4.3 for a list of theme categories, clusters, 
and selected sub-themes. In the text below, quotes from parents are linked to the original 
interview transcripts via a designation which reflects participant number followed by 
transcript line number. 
4.3.b.1 Theme Category 1 - Being the parent of a child with high-risk cancer: 
“This is my child here” [P10.L283].  
The overall experience of being the parent of a child with high-risk cancer 
embodied the weight of being fully responsible for the child’s well-being, and knowing 
that “it’s all on our shoulders.” [P3.L94] This responsibility included the child’s inherent 
full reliance on the parent for all their needs. In addition, this responsibility necessitated 
that parents become an expert in their child’s cancer, find a way to help their child get 
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better, protect their child from undue harm and distress, be vigilant, prioritize their child’s 
needs and desires over everything else, advocate for their child when needed, and 
encourage their child to keep trying. As one parent stated:  
“I look at it kind of like … the movie … where he [the father] and his son 
are in the concentration camps and he's trying to shield his son from the 
horrors and trying to show him the beautiful aspects of life.” [P10.L203] 
This sense of total responsibility meant that parents felt like they knew their child 
and their child’s medical condition better than anyone, and they felt they did not have 
anyone to blame when treatments they agreed to did not work. “If something does 
happen, and knowing that you don't know, you just kind of got to accept it.” [P8.L282] 
Parents sought and primarily achieved alignment with their child regarding the 
treatment plan. They looked to the child for direction and strove for open parent / child 
communication, e.g. “That's the decision we have to let [her] make. If she wants to try 
another one [P1T], if she don't want to try another one, whatever it be.” [P6.L267] Due to 
the parent’s underlying need for their child to agree and cooperate with the treatment 
plan, whenever parent and child were misaligned, the parent sought ways to realign. “I 
didn’t want to be forceful …. I was just very hopeful that she would say, ‘yeah Mom, let’s 
do this’.” [P6.L203] 
Finally, being the parent of a child with high-risk cancer involved parental 
suffering. The emotional burdens parents faced resulted in intense angst – “that pit in my 
stomach” [P3.L352] (see Table 4.3 for full list of emotional burdens). Underlying the 
burdens was the need to make good decisions on their child’s behalf and to ensure the 
time they had with their child was used well. “I just wish I'd had a little bit more power, a 
little bit more strength, a little bit more knowledge.” [P1.L213]  
4.3.b.2 Theme Category 2 - Contending with high-risk cancer: Fighting “this 
beast” [P12.L82].  
Woven throughout parents’ P1T experiences was a pervasive struggle to contend 
with their child’s high-risk cancer. One parent described this as: 
“You almost have a feeling of … hopelessness … you just kind of wonder 
from day to day, well is this the day that we're going to have something 
that is going to work? …even though you feel defeated, you still have that 
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glimmer of hope that there's something that’s going to work. There's got 
to be something that's going to start shrinking it.” [P6.L95 & L101] 
The full continuum of the cancer journey, which extended from diagnosis to the 
child’s survival or death, was focused on overcoming the cancer, underscoring the 
importance of not wasting time with ineffective, intolerable, or unavailable treatments. 
Contending with the cancer was complicated by a perception of the child’s wellness that 
was separate from the child’s cancer status, and made it difficult to accept the cancer 
worsening. “[The doctor] said, ‘Um, the cancer is back.’ And I was like, ‘What?’ I mean 
she never, ever showed signs.” [P8.L192] 
The team parents assembled to help fight the child’s cancer consisted primarily 
of the medical team and close family members, although some parents fortified their 
team with support from other parents of children with similar cancer diagnoses. The 
processes involved with having a team to help in the struggle against the child’s cancer 
included aligning or connecting, becoming misaligned or disconnected, and managing 
misalignment or disconnectedness with team members. Parents who felt disconnected 
from medical team members were reluctant to share those concerns with the team. “It 
was kind of hard to bring up our anxieties... We were just prayerful that we were being 
pushed in this direction [to the P1T] for good reasons.” [P3.L50] 
Parents left no stone unturned in the search for treatments, but had specific 
requirements for acceptable treatment options based on anticipated impact on quality 
of life. Parents were aware that “you necessarily have to start looking at quality of life 
instead of quantity at some point.” [P4.L424] Although parents clung to hope that the 
next treatment would help, they also felt challenged to begin thinking about stopping 
their search for treatment. Catalysts precipitating whether parents decided to stop 
curative treatments are listed in Table 4.3. Parents bore the burden of decision-making 
at potential stopping points as they had no choice but to make a choice. They 
conscientiously approached decision-making by “weighing everything out” [P2.L211], 
balancing potential risks and benefits with expected impact on quality of life. Parents 
were generally able to be decisive in their decision-making, and not look back after 
decisions were made.  
 75 
Being locked in this struggle against the child’s cancer necessitated finding ways 
to manage constant challenges and uncertainty day to day. “You're just on this moving 
treadmill and you're trying to keep up with the speed as it increases.” [P10.L119] 
Parents managed by finding a new norm for their child and family, i.e. by getting “to 
where we could all breathe” [P1.L246]. This resulted in a redefinition of what was 
considered truly difficult or problematic. See Table 4.3 for specific strategies used day to 
day.  
Parents transcended the day to day challenges and uncertainty of their child’s 
struggle with cancer by finding meaning, being grateful, having hope, and relying on 
faith and spirituality. Parents expressed gratitude for how things went for their child, no 
matter the outcome. The sense that “we've been very fortunate” [P10.L397] pervaded 
their experiences as they compared aspects of their journey with what they observed 
other families enduring. Parents’ hope focused on slowing or stopping their child’s 
cancer. At some point though, parents lost hope that their child’s cancer could be 
stopped, regardless of their child’s outcome. They were aware that their child’s life was 
at stake. “We were okay with it [the child’s unexpected death during the P1T]. I mean I 
was not okay with it at the time, but we knew it could happen.” [P8.396] Parents found 
meaning when the time with their child was well spent, and had a sense of achievement 
in the cancer journey – on behalf of their child and for themselves as a parent. 
4.3.b.3 Theme Category 3 - Perceptions of child's experiences: “There is 
something about them that is very, very different” [P10.L184].  
Parents’ widely perceived their child as special in two ways. They perceived their 
child as medically complex, e.g. “he always got the 1% side effect.” [P9.L406]. And, they 
described their child in a very positive light (e.g. brave, optimistic, resilient), from which 
parents conveyed deep pride and derived strength. Underlying parents’ perceptions was a 
cherishing of their child and the time they spent together on meaningful activities. One 
parent shared a story of her daughter’s interaction with another cancer patient:  
“She went over [to a man just diagnosed with cancer] and she said, ‘I just 
want you to know, you got this! You can beat this! … It’s not as bad as 
what people say it is.’ He had said, ‘It’s not?’ She goes, ‘No, you'll have 
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your good days and you'll have your bad days, but you'll get through it, I 
promise.’ …. ‘Another thing, you look good bald, so when you're done 
you might just stay bald.’ He started dying laughing and he said, ‘Well, 
you look good bald too.’ She said, ‘Yeah, it’s just taken me awhile to get 
my baldness.’” [P8.L316] 
From the parent perspective, children’s understanding of the cancer, its 
treatments, and decision-making was influenced by the child’s age and cognitive ability. 
The child’s age impacted their P1T experience as younger children were “too young to 
really have any conversations about what it [the cancer] meant” [P10.L204] and to ask 
tough questions, and did not remember any other way of living. That said, almost all 
parents reported their children being very cooperative with cancer treatments and 
procedures, e.g. “they didn't really balk at it” [P9.L138] and “he never complained” 
[P1.L230]. This reflected a maturity beyond their years that the children developed 
through their cancer journey. Regardless of age, parents described how their child “knew 
how to get what [they] … wanted” [P10.L220] and used their cancer diagnosis to achieve 
their goals. 
The child’s age and cognitive ability influenced parents’ decisions regarding their 
child’s level of involvement in treatment decision-making. All children ages 10 years and 
older without cognitive challenges were described by parents as making their own 
treatment decisions with parental support. Older children and adolescents had this 
decision-making role despite some parents being less certain of their child’s 
understanding of their own cancer, e.g. “I don’t think he realized the extent of how things 
had gotten at that point.” [P2.L166] The lack of parent clarity regarding their child’s 
understanding of their condition occurred despite the child’s presence at and involvement 
in treatment discussions. “The doctors were very good at choosing words that would kind 
of let us know what was going on, but not so much a 12-year-old.” [P2.L158] Parents 
recognized adolescents’ inherent tendency to take risks, and still let them make decisions, 
e.g. “he was a 17-year-old boy, so he was a risk-taker, too. So, that [P1T participation] fit 
right in for him.” [P12.L350] 
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4.3.b.4 Theme Category 4 - The nature of P1T participation: “The further you 
get into a poor prognosis, the easier a phase I trial becomes” 
[P12.L332].  
This theme category reflects the elements of parents’ experiences specific to the 
P1T, and it encompasses a broad range of theme clusters, including underlying 
characteristics of P1Ts, choosing to participate in a P1T, ebb and flow of P1Ts, emotional 
stances towards P1Ts, and the impact of P1T participation.  
The underlying P1T characteristic impacting parents the most was the 
uncertainty of P1Ts; the sense that “nothing’s ever a given” [P1.L71] This uncertainty 
encompassed having to meet criteria to initially start the trial and to continue to the 
next course of the trial, as well as not knowing what the P1T therapy would do to or for 
their child. One parent stated: 
“Nothing's ever a given. Even in medicine that's been proven.…. we knew 
that… everything was a ticking time bomb. … we just knew that certain 
things would not work. … it just seemed like [the P1T] was the one that 
offered the most hope. And, I don't know if that was a tangible hope or 
not.” [P1.L71] 
In addition, the inherent complexity of P1Ts created challenges for parents in 
terms of learning about the clinical trial system and finding specific P1Ts that could work 
for their child. Parents specified that the primary website for finding P1Ts, 
Clinicaltrials.gov160, was confusing to search. Parents were seeking more support in 
learning about clinical trials, e.g. “you really need to find somebody who is going to sit 
down with you and explain the clinical trial process from start to finish, because it's not 
straightforward.” [P10.355]. This included a “resource to really simplify things … [to] lay 
everything out for people… [using] very simple language that's trust-building.” [P12.L538 
& L563] 
Parents understood there weren’t any guarantees that the P1T would help 
against their child’s cancer. Some clearly expressed that “I knew it wouldn’t help [my 
child]” [P5.L264], yet were still willing to participate given their child’s poor prognosis. 
The hope that the P1T would help slow or stop the child’s cancer was reported by all 
parents. Parents were realistic in this hope, e.g. “with these studies … we aren't even 
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looking for the cancer to shrink; we're just looking for it to stay at bay.” [P4.L464] 
Altruism and leaving a legacy were only identified by parents of children ages 12 and 
older as reasons for participation. The appeal of P1Ts was a sense of trying something 
completely novel and of pursuing every possible option to help their child, as well as 
being part of research that potentially could lead to a cure.  
Most parents described the decision to participate in a P1T as easy, and many 
had a sense that the P1T plan “just fell into place” [P1.L99]. Emotional stances towards 
P1T participation varied as the experience unfolded. That is, parents at times embraced 
the P1T and all of its unknowns, felt special for being asked or chosen to participate, 
were fearful of P1T unknowns and potential toxicities, and deemed the P1T as more 
burdensome than other treatments (see Table 4.3 for full list). Many parents 
experienced frustration with the inflexibility of the P1T protocol at some point. One 
parent who would later become involved in childhood cancer advocacy expressed how 
at the time of P1T enrollment, he had “no idea, absolutely no idea” [P10.L117] what he 
was getting into. Despite feeling negative emotions at times, almost without exception 
parents did not regret their child participating in a P1T and recommended P1Ts to other 
parents of children with cancer.  
Overall, parents approached the P1T as “just another medicine” [P5.L138] for 
their child’s cancer. Specific advantages parents experienced while participating in a P1T 
included feeling better informed and cared for during the P1T, and having access to 
more resources and opportunities by being at a larger P1T center. Disadvantages 
included having to wait to start P1T therapy, burdens of extra and longer medical 
appointments as well as additional procedures and venipunctures, and a sense of their 
lives revolving around the P1T. Parents strove to minimize the burdens of P1T 
participation by incorporating enjoyable activities around required P1T appointments 
(i.e. by making visits to the P1T center feel like “a family trip… a little get-away”) 
[P8.L121].  
Some parents described the meaning attached to blood samples taken 
specifically to support research. “He was all excited about doing that, … sending samples 
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out to wherever it needed to go.” [P5.L128] However, an appreciation of the 
significance of research-only lab draws and procedures did not offset the additional 
burden they created for parents and children. Parents whose child was surviving and 
still involved with P1Ts described the specific burdens associated with P1T research-only 
lab draws and procedures.  
“We had to sit there for nine hours … because they had to draw his blood 
every hour. …. Just sitting there doing absolutely nothing and they 
weren't doing anything for us… And what sucked was he needed one 
blood draw 24 hours after. It was we went all the way down there, so it 
was over an hour drive. I counted we were in the clinic for seven minutes, 
and we left and drove back an hour.” [P4.L389 & L393]  
Parents were more receptive to research-only lab draws and procedures that 
occurred while their child was still participating in the P1T. When there were 
requirements asked of participants after the child’s removal from the P1T, parents were 
far less willing to comply unless these procedures could be planned to coincide with 
other elements of the child’s medical care. However, parents did feel empowered to 
refuse post P1T research-only labs and procedures on their child’s behalf, when they felt 
that the burden was too great.  
“It's like you feel you aren't good enough to get the drug, but they still 
want to get some data from you. …. They wanted us to go in for lots of 
blood work and even scans, and we're like, ‘No. If he can't get the drug 
we're not going to do it.’ “ [P4.L96 & L99]  
Most parents were aware that the P1T protocol guided decisions made about 
their child’s medical care during the P1T. Parents viewed the P1T protocol as 
mandatory, took their role as parents of a P1T participant seriously, and strove to 
always comply with protocol requirements. However, many parents struggled with a 
sense of not being in control, feeling compelled to comply with the P1T protocol, and a 
sense that their child’s medical care was not the primary priority of the P1T. Parents’ 
frustration with the P1T protocol flourished when they deemed that their child’s best 
interests were not in line with protocol requirements. “If the doctors don't even blink an 
eye because there's really nothing wrong with those [lab] numbers, why are we getting 
kicked [out of the P1T]?” [P4.L341] Although most parents continued to comply with the 
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P1T protocol requirements even when they were frustrated, one parent described 
defying the protocol requirements when they felt their child’s medical care and well-
being was being significantly compromised.   This episode occurred in response to the 
requirement that treatment for the child’s progressing cancer stop for several weeks 
before starting the P1T, in order to avoid medication interactions:  
“I was not about to sit back during that watch period and not administer 
any treatment to her. We still had drug left over from the first phase I 
and I will go on record as saying, we administered some of that drug to 
her. ... I was not going to sit idly by.” [P10.L285 & L292] 
There was evidence that P1T participation impacted how a parent managed their 
child’s symptoms. “Him being sick right now … we're trying not to give him any Tylenol 
or anything that could whack his body out.” [P4.L343] This resulted from an overriding 
fear that additional medications could exacerbate toxicities (e.g. liver or renal 
dysfunction) and cause the child’s premature removal from the P1T. In addition, some 
parents were not educated about palliative care and hospice services until late in the 
child’s illness. “Nobody ever really counseled us on that. I also had this stigma about 
hospice services because I thought that was giving up, but it turns out it was a very good 
decision.” [P10.449] 
There were unique aspects of participating in a P1T related to the use of oral 
medications. Although parents appreciated not having to go to the medical center for 
therapy, they struggled with their child’s dislike of oral medications and difficulty 
swallowing pills (e.g. “taking [oral] medicine is the worst” [P8.L255]). They also struggled 
with restrictions on when their child could eat and drink (i.e. due to the need to ensure 
the oral medication is absorbed properly eating and drinking is restricted for 1 to 2 
hours before and after each dose). “It felt worse, the extra fasting and then trying to 
support her emotions, and ‘I’m so hungry’.” [P3.L334]. One parent’s experience was that 
the eating and drinking restrictions exacerbated the nausea and vomiting her child 
experienced with the oral medication. “She wasn't able to eat anything, and then she 
had to take this medicine, and then she had to wait an hour afterwards before she could 
eat anything. It would just really make her extremely sick.” [P6.L82] P1T protocols with 
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oral medications could also be more problematic to manage when the child experienced 
toxicities and the medication was given daily without a break. “This is just every day 
take the pill, feel like crap. Take the pill, feel like crap, you know?” [P3.L266]  
4.3.b.5 Theme Category 5 - Remembering and forgetting: “Sometimes your 
brain kind of blocks things” [P6.L12].  
All parents described a fogginess in their memories of their child’s participation in 
a P1T and cancer treatments in general, e.g. “a lot of it is a blur.” [P10.109] This fogginess 
meant that many specific details were not remembered. One parent shared:  
“I'd like to forget it completely... Again, the Ronald McDonald House, … 
the activities we did, the love of the city are all positives. The treatment 
itself, yeah, I'm really not interested in remembering a lot about it.” 
[P9.L413] 
Parents whose child was surviving and continuing to pursue P1Ts remembered the 
specific challenges of P1T participation the clearest. Regardless of how much time had 
lapsed, parents remembered seminal events very clearly, including when they received 
particularly devastating news or were deeply offended by health care providers. Parents 
reported that younger children who were long-term survivors did not “remember 
anything about … cancer treatments” [P11.L382] in the long run, although they 
“remember some of the happy things” [P11.L351] associated with the cancer treatment 
(i.e. playing with child life specialists). Most parents were not concerned with their 
challenges remembering P1T details, and even took comfort in not remembering.  
4.3.c The Essential Structure  
Pervasive throughout parents’ descriptions of their lived experiences during P1T 
participation was a sense of running out of time to find an effective treatment for their 
child, and their need to use well the time they had with their child. Despite unique aspects 
of P1T participation, parents’ experiences were not focused on the P1Ts themselves. 
Instead, parents were focused on their role and responsibilities as a parent, the 
specialness of their child, and their child’s contending with aggressive high-risk cancer to 
survive. Parents’ perceptions of their child’s experiences reflected a sense of pride in their 
child and how their child dealt with the cancer and its treatments. What parents 
 82 
remembered following participation in a P1T reflected what stood out in the experience, 
and how parents managed the P1T experience. Particularly important aspects of the P1T 
experience included the connection with the health care providers who managed the 
child’s care during the P1T, making the choice to continue trying to slow or stop the child’s 
cancer by participating in a P1T, and being burdened by additional requirements when 
participating in a P1T.  
4.4 DISCUSSION 
The purpose of this study was to address the gap in our understanding of P1T 
participation for children with cancer or their parents, by identifying the fundamental 
commonalities and meaning of the P1T experience. The overarching thread throughout 
parents’ descriptions of their experiences was “we don’t have time to waste” [P12.L557]. 
All participants recognized that, due to the advanced nature of their child’s cancer, “the 
commodity is time, and you run out of it, and you don’t get it back.” [P12.L455] The 
meaning of using time well differed between families, and varied within each families’ 
cancer journey. In some situations, it was a reason for participating in a P1T, in other 
situations it was a reason to stop. Further research is needed to better understand 
parents’ decision-making related to stopping curative treatment efforts for their child, as 
well as to understand the role children should have in this decision. 
Ethicists and clinicians have proposed that the potential benefits of pediatric 
oncology P1T participation may include improved QOL and hope.13-16,77,85-87 Although 
this study did not attempt to assess QOL benefits associated with P1T participation, it 
did find some hope benefit. Study findings confirmed that P1T participation fosters hope 
to slow or stop the cancer. A potential risk of P1T participation posited in the literature 
was the fostering of unrealistic hope.13-15,85-87 Findings did not indicate parents had 
unrealistic hope. arents were able to be realistic in their expectations of direct benefit 
for their child from the P1T therapy. Parents were fully aware that their child’s life was 
at stake, and that the advanced status of their child’s cancer made it unlikely their child 
would be cured. Parents also seemed to derive benefit from their child’s P1T 
participation through the sense of having tried everything possible, including a novel 
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investigational therapy, to help their child. A prospective research study is needed with 
parents to confirm that these benefits, which were reflected on retrospectively by 
parents, are also experienced by parents during P1T participation.  
Another risk of P1T participation identified in the literature was the burdening of 
children with additional medical procedures and toxicities.13-16,77,85-87 This study found 
the burdens of P1T participation for children and parents included additional medical 
procedures, toxicities, and medical appointments. This study also added to our 
understanding of the unique burdens associated with oral medications, which was not 
previously identified in the literature. It is important to be aware of the potential issues 
with oral medications when presenting treatment options to parents and children, as 
clinicians and P1T researchers may overestimate the burdens of intravenous therapy 
administered in a medical clinic or hospital. P1Ts with oral medications that involved 
eating and drinking restrictions were particularly burdensome for parents, as they had 
at times to deny the requests of their child with cancer for food and drink. Parents took 
the requirements of the P1T protocol seriously and strove to comply, even when 
compliance was burdensome.  
Inconveniences associated with research-only specimens and procedures were 
also described in detail, suggesting that for some parents P1T-specific tests and 
procedures caused significant burden. Interestingly, no parent mentioned the incentive 
that was provided to participants to acknowledge the burdens associated with research-
only lab draws. This suggests that the incentive was not coercive but raises questions of 
whether the amount of the incentive was sufficient to reflect the burden experienced by 
parents and children, and whether the distribution of the incentive could be enhanced. 
It is also possible that no incentive would ever sufficiently reimburse families for time 
lost. Currently, there are no recommended guidelines for incentive distribution, beyond 
what is required by institutional review boards. Many centers may logistically provide 
the incentive to P1T participants with the first research-only lab draw, rather than 
waiting until the completion of the lab draws. In addition, parents tended to be 
reluctant to continue with research-only lab draws and procedures after their child was 
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removed from the P1T, unless these coincided with other medical care provided to the 
child. P1T researchers should consider the importance of post P1T research-only lab 
draws and procedures and consider providing additional incentives to acknowledge and 
offset the additional burden created for parents and children.  
A final risk of pediatric oncology P1T participation identified in the literature was 
limitations on opportunities for palliation.13,14,85 The study findings provided evidence 
that P1T participation could impact how parents managed their child’s symptoms. The 
need to ensure the child could continue in the P1T, without held doses of therapy, for 
parents sometimes overrode the child’s symptom management. In addition, some 
parents were not educated about palliative care and / or hospice services until late in 
the child’s illness. The latter does not seem to reflect the impact of P1T participation, 
but instead appears to reflect the reluctance of clinicians and parents to discuss 
palliative care and / or hospice when there is a focus on continuing curative treatment. 
Indeed, late palliative care and / or hospice referral has previously been described in the 
literature as a significant problem in general for children with advanced cancer.161-163 
These findings highlight the need to simultaneously provide effective palliative care 
throughout the child’s P1T participation.41,164 
P1T decision-making and consent processes were demonstrated in this study to 
be impacted by the quality of communication between the child, parent, and health-
care providers. Empiric research has previously identified challenges educating potential 
participants about pediatric oncology clinical trials and lapses in pediatric oncology P1T 
consent processes.27,132,133,165,166 This study confirmed that parents need more support 
and better education regarding the clinical trial system, e.g. regarding intricacies of and 
motivations behind each phase of clinical trials. Parents in this study also described 
challenges identifying appropriate P1Ts. ClinicalTrials.gov is the database which provides 
information about all clinical trials conducted throughout the United States.160 
Clinicaltrials.gov was recognized by parents as containing the most comprehensive 
information available on existing trials; however, parents struggled with obtaining 
information on P1Ts from the site. In addition to what is described in the literature, 
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parents in this study also specifically highlighted how double-protection (i.e. the 
phenomenon of both parent and child attempting to protect each other) negatively 
impacted open communication and consent processes.128 This warrants clinicians and 
P1T researchers paying particular attention during P1T consent conversations to the 
transparency of communication. 
Study findings indicated that parents did not remember many details of their 
child’s cancer treatment experiences in the long term. However, further research is 
needed to understand whether not remembering is a potentially problematic repression 
of traumatic memories or a less worrisome natural adaptation following a period of 
significant distress.  
Overall, parents did not regret their child participating in a P1T and would 
recommend P1Ts to other parents of children with cancer. There was a notable 
exception as one parents’ experience with the P1T was substantively more negative, 
despite their child having prolonged stable disease with tumor shrinkage from the P1T 
therapy. This parents’ P1T experience was fraught with a sense of disconnectedness from 
the medical team from beginning to end, the child fighting taking the oral medication, as 
well as with doubts as to whether they were doing the right thing for their child. The 
reasons behind this were difficult to fully appreciate without having captured the medical 
team’s perspective. However, this parent was also the only one who really struggled with 
the initial decision to participate in a P1T and described an ethically problematic situation 
related to trial participation. It is important to not dismiss this one parent’s experience as 
an outlier, as it may reflect other previously unreported problematic P1T experiences. The 
researchers recommend that in future research, an in-depth multiple case study be 
conducted when any ethically problematic situations are identified, in order to capture 
the perspectives of the parent, medical team, and child. In addition, P1T researchers and 
clinicians should explore with parents the reasons behind hesitancies to participate or 
continue in a P1T. It is particularly important that P1T researchers and clinicians are aware 
of the significance of an offer of a P1T for parents of children with high-risk cancer, and 
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the impact that a pre-existing parent / provider relationship has on parents’ ability to 
decline a P1T offer or to share concerns with providers during a P1T.  
4.4.a Limitations 
The primary limitations of this study were the lack of racial, ethnic, and social 
diversity in the accrued sample, and the lower-than-anticipated response rates from 
medical centers creating concerns for self-selection bias by those who chose to 
participate. In addition, a fuller description of pediatric oncology P1T experiences would 
include the child’s perspective. Due to the shortened life expectancy of children enrolled 
in P1Ts, and the relatively small number of children enrolled per trial, obtaining the 
child’s perspective was not feasible outside of a prospective, multi-center study. Lastly, 
this study captured parents’ experiences retrospectively and parents’ perceptions of 
their experiences may have altered with the passing of time.     
4.5 CONCLUSIONS 
Study findings are generally reassuring to P1T researchers and pediatric 
oncologists who consider recommending P1Ts for children with cancer. For parents of a 
child with high-risk cancer, a P1T represents a novel treatment option with potentially 
more acceptable toxicities. Although some concerns were raised regarding the 
experiences of parents and children in P1Ts, these reflect opportunities for 
improvement. Parents who describe burdens in P1Ts would not dissuade other parents 
of children with high-risk cancer from participating, and indeed would continue to 
pursue other P1Ts for their own child with cancer.  
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TABLE 4.1  EXAMPLES OF SIGNIFICANT STATEMENTS, RESTATEMENTS, AND 
FORMULATED MEANINGS DEVELOPED DURING DATA ANALYSIS  
ID Significant Statements  
(From Original 
Interview Transcript) 
Restatements  
(Developed by the 
Researchers) 
Formulated Meanings  
(Developed by the 
Researchers) 
P3.L55 We just kept telling 
ourselves that even if 
we have these 
hesitancies and we 
think that may be... 
pushing big pharma or 
whatever, maybe it's 
also because they want 
the best for [child’s 
name].  
Family kept telling 
themselves that even if 
they have these 
hesitancies and family 
thinks that the doctors 
may be pushing big 
pharmaceutical 
companies or 
whatever, maybe it’s 
also because the 
doctors want the best 
for their child.  
Aware of competing 
interests. Wary of 
clinical trials and 
interests of big 
pharmaceutical 
companies. Hoping the 
doctors were involved 
in clinical trials because 
it was best for children 
with cancer, and for 
their child; for altruistic 
and not ambitious 
reasons. 
P5.L128 He was all excited 
about doing that as 
well, sending samples 
out to wherever it 
needed to go. Knowing 
that it wouldn't help 
him, but it would 
hopefully help other 
people in the future.  
 
Adolescent was excited 
about sending blood 
for research. 
Adolescent knew that 
sending the blood 
would not help him. 
Adolescent wanted to 
help others in the 
future. 
 
It was important to the 
adolescent to 
contribute to future 
scientific advances. 
Adolescent understood 
that the research 
samples would not 
provide direct benefit 
to himself.  
Proud of adolescent’s 
selflessness and for 
who adolescent was – 
someone for whom 
altruism was an 
important part of the 
reason for being 
involved with research.  
P8.L256 I think she would have 
rather - and I don't 
really blame her since 
she had a port, or 
whatever - she would 
rather go have 
medicine put in her 
than have to take a pill.  
Parent thinks child 
would have rather go 
have medicine put in 
[port] than have to 
take a pill. 
Would have been 
easier to do IV 
medications than to 
have to take 
medications at home. 
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TABLE 4.2  CHARACTERISTICS OF THE SAMPLE AND THEIR P1T EXPERIENCES* 
Item n (%) 
Child’s Diagnosis (N=10 children)  
Sarcoma 6 (60) 
Brain Stem Glioma 1 (10) 
Other Brain Tumor 2 (20) 
Neuroblastoma 1 (10) 
Leukemia 1 (10) 
Child’s Status (N=10 children)  
Deceased 6 (60) 
Surviving and on Treatment 2 (20) 
Surviving and in Extended Remission 2 (20) 
Timing of Removal from P1Ts (N=15 trials)  
Middle of Course 1 3 (20) 
End of Course 1 3 (20) 
During Course 2 2 (13.3) 
End of Course 3 1 (6.7) 
After Course 3 5 (33.3) 
Completed Trial 1 (6.7) 
Reasons Removed from P1Ts (N=15 trials)  
Adverse Events / Toxicities 5 (33.3) 
Disease Progression 8 (53.3) 
Death 1 (6.7) 
Completed Trial 1 (6.7) 
Best Overall Response to P1Ts (N=15 trials)  
Progressive Disease 5 (33.3) 
Stable Disease 5 (33.3) 
Partial Response 2 (13.3) 
Complete Response 1 (6.7) 
Inevaluable / Unknown Response 2 (13.3) 
 
* N=11 parents of N=10 children, enrolled in a total of N=15 phase I clinical trials. 
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TABLE 4.3  LISTING OF IDENTIFIED THEME CATEGORIES, THEME CLUSTERS, AND THEMES 
WITH SELECTED SUB-THEMES 
Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
Being a parent of a child with high-risk cancer: “This is my child here” [P10.L283] 
• Being fully responsible for child's well-being: “It's all on our shoulders” [P3.L94] 
• Child fully relying on parent 
• Advocating for child when needed: “If you don't, then your child's 
going to get pushed around” [P10.L382] 
• Protecting child 
• Being vigilant 
• Prioritizing child’s needs and desires over everything else 
• Encouraging child to keep trying: “He wasn't going to be at home ... 
in bed giving up” [P1.L205] 
• Needing to find a way to help child get better 
• Needing to be an expert 
• Not having anyone to blame if treatments don't work 
• Knowing child and child's medical condition better than anyone: 
“They thought they knew better than I did” [P10.L434] 
• Doing everything possibly can for child 
• Aligning with child: “We would quit whenever she wanted to” [P8.L15] 
• Looking to child for direction: “If that's what she wants to do ... she 
knows how she feels” [P6.L259] 
• Striving for open communication with child: “We don’t surprise her 
with anything. We talk about things.” [P3.L253] 
• Needing child to agree with plan: “I was just very hopeful that she 
would say, yeah mom, let's do this” {P6.L205] 
• Being on the same page: “She was willing to do it and we were 
willing to do it, so we tried whatever” [P8.L53] 
• Becoming misaligned: “When she started resisting it was very 
weird for us because she's always been so accepting” [P3.L272] 
• Parental suffering 
• Indescribable angst 
• Watching child suffer 
• Fearful of harming child 
• Losing oneself in child's journey 
• Feeling isolated and alone 
• Doubting OR questioning own abilities 
• Living with regrets: “I just wish I'd had a little bit more power, a 
little bit more strength, a little bit more knowledge” [P1.L213] 
• Feeling overwhelmed with what have to handle: Trying to keep up 
with moving treadmill as speed is being increased 
Contending with high-risk cancer: Fighting “this beast” [P12.L82] 
• Continuum of the cancer journey: The life cycle of cancer 
• Beginning the journey: Life altering diagnosis of cancer 
• The insidious nature of cancer 
• Cancer not going away 
• A time bomb ticking beneath the surface  
• Cancer becoming a visible or tangible reality 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Trapped in unrelenting cycle of remission and 
relapse 
• Cancer relentlessly taking over 
• Enduring endless treatments 
• Perception of wellness muddying the waters: “Cancer kids can get 
sick” [P4.L147] 
• Dichotomy of having cancer and being well: “You 
would not look at her and know that she had a 
terminal diagnosis” [P10.L233] 
• Becoming unwell during cancer journey 
• Recovering from being unwell 
• The journey ending 
• Entering hospice 
• Deciding that child was just ready to go 
• Child dying from cancer or complications of 
cancer 
• Child dying unexpectedly 
• Sadness of child missing out on good parts of life 
• Family disintegrating after child died 
• Child being a long-term survivor 
• Forming a team 
• Establishing and maintaining connections with medical team 
• Getting the right medical team 
• Having expectations of medical team 
• Connecting with members of medical team 
• Disconnecting with medical team 
• Unconnected with medical team members 
• Managing family dynamics 
• Aligning 
• Misaligning 
• Managing misalignment 
• Being supported by other parents and children with high-risk 
cancer 
• Child taking comfort in presence of other 
children with cancer 
• Finding other parents who understood and had a 
similar point of view 
• Leaving no stone unturned: Searching for tolerable and effective treatment options 
• Looking everywhere for the best treatment option 
• Being supported by others in search for options 
• Needing to always be ready with other treatment 
options 
• Traveling when needed to find treatment 
options: “Then you've got to travel” [P10.L149] 
• Trying complementary therapies and herbal 
supplements along with other treatments 
• Struggling to find a treatment option that meets 
their requirements 
• Having requirements for treatment options 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Making exceptions in certain circumstances 
• Turning down treatment options that don't meet 
requirements 
• Vicious cycle of trying to find an effective treatment that child can 
tolerate: “Hoping that one works, one that we can stay on” 
[P4.L461] 
• Role of doctors in search for treatment options 
• Relying on doctors to provide treatment options 
• Doctors continuing to provide treatment options 
• Discussing treatment options together with 
medical team 
• Seeking input from different trusted medical 
team members 
• To stop or not to stop: Stopping point as a moving target 
• Moving onto next treatment 
• Needing to do something to stop cancer 
• Not ready to quit: “We didn't want to give up 
yet” [P9.252] 
• Not willing to waste time in search for an 
effective and tolerable treatment 
• Deciding to stop curative treatments 
• Recognizing at some point, when cancer is taking 
over, have to stop treatment 
• Passively making decision to stop curative 
treatment 
• Accepting child is going to die 
• Catalysts precipitating or hindering decisions at potential stopping 
points 
• Availability of good or reasonable options 
• Child's quality of life 
• Level of understanding of seriousness of child's 
condition 
• Effectiveness of last treatment 
• Tolerability of last treatment 
• Believing there is a treatment out there that's 
going to work 
• Wanting to be able to explore all possibly 
effective treatment options 
• Bearing burden of tough decisions 
• No choice but to make a choice 
• Between a rock and a hard place: Start another 
cancer treatment or let child die 
• Ways of decisioning 
• Being decisive: “Let's do it” [P1.L269] 
• Being hesitant or uncertain 
• Needing time to make a decision 
• Conscientiously thinking everything through 
before making a decision 
• Seeking input from others 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Wanting to be told what to do 
• Taking ownership of decisions related to child's 
care 
• Taking risks 
• Trusting gut instincts 
• Spirituality in decision-making 
• Angst of having to make a decision 
• Wondering if doing the right thing 
• Becoming desperate 
• Being overwhelmed 
• Being unprepared 
• Feeling defeated 
• Questioning own ability to make a decision 
• Not knowing what to do: “We just didn't know” 
[P10.L512] 
• Living with choices made 
• Managing day to day - Doing the best you can day to day 
• Facing constant challenges or problems 
• Having to do things that were difficult or 
unpleasant: “It was tough!” [P10.L324] 
• Having to be self-reliant 
• Compelled to juggle responsibilities 
• Compelled to make compromises 
• Unable to enjoy life 
• Becoming swept up in tide of negativity 
• Living with uncertainty 
• Having to wait: “We'll have to see” [P10.442] 
• Experiencing unexpected interruptions to plans 
• Not being able to plan too far into the future 
• Finding a new norm: “It all just started to click a little bit better” 
[P1.266] 
• Seeking normalcy 
• Finding comfort in routine: “That was just our 
routine” [P8.L143] 
• Redefining what is considered difficult or a real 
problem: “Hard... it's all relative I think” 
[P10.L277] 
• Strategies for managing day to day 
• Focusing on the present 
• Trying to solve or prevent problems 
• Following a plan diligently 
• Having transcendent goals 
• Rolling with the punches 
• Gaining expertise and knowledge over time: 
“Now I know a lot more” [P10.L145] 
• Accepting help 
• Maintaining connections with family, friends, and 
social network 
• Relying on pre-existing strengths 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Setting boundaries 
• Being proactive 
• Being realistic with expectations 
• Finding time and space to recover 
• Avoiding information and difficult discussions 
• Transcending the struggle against cancer 
• Finding meaning 
• Using time well 
• Sense of achievement or pride in cancer journey 
• Being a part of something bigger than own 
journey 
• Valuing research and participation in research 
• Believing that treatments helped child in some 
way 
• Continuing bonds with child after child's death: 
“That's a part of her so we'll just leave it there” 
[P8.L151] 
• Being grateful for how things went: “We've been very fortunate” 
[P10.L397] 
• Being better off than others 
• Having resources and people available 
• Having special moments and memories 
• Child maintaining a good quality of life 
• Having hope 
• Hoping to slow or stop cancer 
• Hoping for quality of life in time remaining 
• Hoping can help others 
• Hoping P1T participation was meaningful 
• Relying on faith and spirituality 
Nature of P1T participation: “The further you get into a poor prognosis, the easier a phase I trial 
becomes” [P12.L332] 
• Underlying characteristics of P1Ts 
• Uncertainty of P1Ts: “Nothing's ever a given” [P1.L71] 
• Having to qualify for a P1T 
• No guarantee P1T will work: “It's a crapshoot” 
[P10.L138] 
• Not knowing what P1T therapy would do to or 
for child 
• Abnormal lab values having the potential to 
remove child from P1T 
• Complexity of P1Ts 
• Trying to become fluent in the clinical trial 
system 
• Understanding complexity and logistics of P1Ts 
• Not understanding full complexity of P1Ts 
• Having a clear plan 
• Therapy given in outpatient setting 
• P1Ts having the most requirements in the first cycle(s) 
• P1Ts being administered the same, regardless of institution 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Institutions and medical teams influencing or determining how the 
P1T experience unfolds for families 
• Choosing to participate in a P1T 
• Reasons for participating in a P1T 
• Hoping that P1T will help slow or stop child's 
cancer: “It is your hope!” [P10F.L42] 
• Believing that research will find cures for cancer 
• Wanting to try something completely novel: “We 
wanted to try something that had not been tried 
before” [P10.L33] 
• Altruism 
• Participating in research as legacy: “You're 
leaving something behind” [P12.L325] 
• Doctor recommending or suggesting P1T 
• P1T available when needed 
• P1T anticipated to have minimal impact on 
quality of life 
• Other parents of children with cancer 
commending their experiences with clinical trials 
• Being willing by nature to take risks 
• Child having to assent to participate in P1T 
• Many steps involved with enrolling in a P1T 
• Ebb and flow of P1Ts 
• P1T plan “just fell into place” [P1.L99] 
• Interruptions to P1T plan 
• Holding P1T therapy so child could recover from 
side effects 
• Restarting P1T, even after things went wrong 
• Trying again at a lower dose of P1T therapy 
• Trial conclusion 
• Being removed prematurely from P1T 
• Deciding to stop participating in P1T 
• Reasons for leaving or being removed from P1T 
• Being concerned only with continuing child's 
cancer treatment as soon as possible 
• Being asked for child to have additional lab work 
and tests done after removal from P1T 
• Outcomes of P1T participation 
• Cancer improving 
• Cancer remaining essentially stable 
• Cancer getting worse 
• Having clinical improvements 
• Dying unexpectedly during P1T 
• Emotional stances towards P1Ts 
• Embracing P1T, including unknowns 
• P1T as an easy or obvious decision 
• Being unafraid: “There really was no fear” 
[P1.L284] 
• Taking comfort in what is known about P1T drugs 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Not regretting participating 
• Relief in doing something to stop the cancer 
• Seeing only risk as potentially wasting time on an 
ineffective treatment 
• Sense of security in knowing can withdraw from 
P1T at any time and get backup chemotherapy 
• Feeling special for being asked or chosen to be in P1T 
• Initial resistance to participating in a P1T 
• P1Ts as least desirable type of treatment option 
• Not wanting child to be a guinea pig 
• Being fearful 
• Fearing P1T unknowns 
• Fearing side effects 
• Overriding fear of child being prematurely 
removed from P1T: “People can get sick, and if 
we had just been in that perfect timing once 
again we could've got kicked off, but a week later 
he's going to feel just fine” [P4.L334] 
• Being afraid that P1T didn't or won't work against 
child's cancer 
• Worrying about child having long term health 
damage from P1T therapy 
• Appreciating that P1T experience could be even harder 
• Deeming P1T as being more burdensome than other treatments 
including conventional chemotherapy, other clinical trials, or stem 
cell transplant 
• Child hating to take the P1T drug 
• Feeling used as a means to an end 
• Believing in the end that P1T was worth burdens 
experienced 
• Frustration with inflexibility of P1T protocol 
• Seeing child as not being the priority of the P1T 
• Feeling that P1T protocol focuses on lab values 
that don't matter 
• Viewing P1T protocol as mandatory 
• Trying unsuccessfully to bend the rules 
• Defiantly breaking the rules: “I was not going to 
sit idly by” [P10.L292] 
• Not understanding at the time what getting into when enrolling in 
P1T: “Back then, I had no idea, absolutely no idea” [P10.L117] 
• Becoming doubtful regarding effectiveness of 
P1Ts and clinical trial system after P1T 
completed: “The paradigm has to be shifted” 
[P10.L143] 
• Not caring about P1T complexities or logistics 
• Not blaming P1T for bad experiences 
• Others having negative opinions about P1Ts 
• Impact of P1T participation 
• P1T as “just another medicine” [P5.L138] 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Advantages of P1T 
• Feeling well informed during P1T 
• Feeling well cared for during P1T 
• More resources and opportunities available at 
P1T center 
• Disadvantages of P1T 
• Having to wait to be able to go onto a P1T 
• Being burdened by participating in P1T 
• Life revolving around P1T 
• P1T protocol and decisions beyond parent's 
control 
• Child not being the priority during the P1T 
• Family's insurance not covering P1T 
• Unique aspects of oral P1T therapy regimens 
• Disliking taking oral medications 
• Having to work around child's difficulty 
swallowing pills 
• Being restricted on when child can eat or drink 
• Not ever getting a break from taking the P1T 
drug or experiencing its side effects 
• Not having to go to the hospital to get the P1T 
therapy 
• Experiencing side effects or complications during P1T therapy 
• Side effects being intolerable 
• Becoming critically ill during P1T 
• Vital organs being impacted by P1T therapy 
• Not really being burdened by side effects 
• Importance of timing of onset of side effects 
during P1T 
• P1T protocol exacerbating side effects 
• Experiencing side effects from supportive 
medications in addition to side effects from P1T 
therapy 
• Not feeling burdened by P1T participation 
• Short part of cancer journey: “This is a really short story” [P4.L8] 
Perceptions of child's experiences: “There is something about them that is very, very different from kids 
who deal with non-life-threatening illnesses” [P10.L184] 
• Seeing child as special 
• Child having special needs 
• Perceiving child as medically complex: “She is a very complex 
person … with all her conditions” [P3.L183] 
• Seeing child in a very positive light - brave, optimistic, resilient: 
“She was amazing!” [P10.L271] 
• Seeing child as stronger and more resilient than 
parent: “I couldn't have done half the stuff she 
did” [P8.L293] 
• Deriving strength from child: “I drew my strength 
from her” [P6.L240] 
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Theme  
Categories 
Theme  
Clusters 
Themes Selected  
Sub-Themes 
• Having pride as a parent for who child is or was: 
“That makes a parent proud!” [P6.L275] 
• Child's age impacting their P1T experience: “She was too young” [P10.L205] 
• Child being too young to understand meaning of having cancer or 
to ask difficult questions: “She was too young to have any 
conversations about what it meant” [P10.L204] 
• Child being very young and not knowing any other way of living: 
“This was what was normal for her” [P10.L353] 
• Child not protesting against treatments or procedures: “He never complained” 
[P1.L230] 
• Child being very active in decision-making: “We would leave it up to her: [P6.L264] 
• Child mature beyond years because of what went through in cancer journey: “Very 
mature for her age” [P6.L33] 
• Adolescent's willingness to take risks impacting decision-making: “He was a risk-
taker so that fit right in for him” [P12.L350] 
• Child playing the cancer card: “She knew how to get what she wanted” [P10.L220] 
• Being uncertain of child's understanding of their own cancer: “I don’t think he 
realized the extent of how things had gotten at that point” [P2.L166] 
Remembering and forgetting: “Sometimes your brain kind of blocks things out after certain things 
happen” [P6.L12] 
• Fogginess and uncertainty: “A lot of it is a blur” [P10.109] 
• Not remembering specific details 
• Remembering incorrectly 
• What is remembered by parents 
• Remembering some details: “I do remember that” [P1.L101] 
• Remembering important moments in particular: “I'll never forget 
this” [P10.L455] 
• What is remembered by children 
• Child only remembering happy times: “She remembers some of 
the happy things” [P11.L351] 
• Child not remembering cancer treatments in the long run: “She 
doesn't remember any of the pain” [P11.L351] 
• Emotional stances towards remembering and forgetting 
• Lack of concern over difficulties remembering: “Of course I don't 
remember a lot of the details” [P2.L40] 
• Taking comfort in not remembering: “I don't remember it being a 
big deal” [P12.L245] 
• Wanting to remember more: “I wish I could remember better” 
[P2.L187] 
• Wishing could forget experience of treatment completely: “I'm not 
really interested in remembering” [P9.L416] 
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 This chapter summarizes the overall findings of this dissertation, discusses 
strengths and limitations of the dissertation, and provides recommendations for future 
research and pediatric oncology P1T design and management. 
5.1 INTRODUCTION 
 The purpose of this dissertation was to investigate the phase I clinical trial (P1T) 
participation experience for children with cancer and their parents by: (1) assessing 
what is currently known about the participation experience, (2) exploring ways to 
understand and assess treatment burden and QOL during participation, and (3) 
interviewing parents about the experience of having a child participate in a P1T. 
Following a review of the literature, two studies were conducted: a longitudinal pilot 
study of 13 parent and child dyads who enrolled in a pediatric oncology early phase 
clinical trial at the recruiting institution, and a phenomenological study of 11 parents of 
children with cancer who participated in pediatric oncology P1T. Findings are 
formulated in three chapters (Chapters 2 through 4). This chapter synthesizes the key 
findings from those chapters, discusses strengths and limitations of the dissertation, and 
provides recommendations for future research and pediatric oncology P1T design and 
management. 
5.2 SUMMARY OF FINDINGS 
The first key finding was that participants in pediatric oncology P1Ts overall had 
positive experiences during their participation. Parents whose child with cancer 
participated in a P1T strove to use the time they had remaining with their child well. 
Although the prognosis for children enrolled in a P1T is poor, in general these trials were 
safe, had manageable toxicities, and offered slight hope for at least stabilization of 
disease for several months.1,2,37-40 P1T participation fostered hope to slow or stop the 
child’s cancer, provided a sense of trying everything to fight the child’s cancer, 
supported a therapeutic alliance with healthcare providers, contributed to cancer 
research, and provided meaning for participants’ lives. Even though potential harm 
could be created by unrealistic optimism or hope during P1T participation, the findings 
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of this dissertation indicated that parents were able to be realistic in their hope of direct 
benefit for their child.15,18,41,80,115 Overall, parents did not regret their child’s 
participation in a P1T and would recommend P1Ts to other parents of children with 
cancer, regardless of the child’s outcome.  
The second key finding was that participants in P1Ts were burdened to varying 
extents by their participation. These burdens included increased hospital visits, 
additional medical procedures and tests, toxicities related to the P1T therapy, and 
additional time in hospital and / or clinic that detracted from time at home and usual 
activities. These burdens extended to other family members who supported the child 
and parents through the trial. Participants’ experiences of burdens varied based on the 
specific circumstances and child / family demographics including: distance from P1T 
center, age of child and other siblings, child’s level of wellness, level of external support, 
and alignment with health care providers. Parents of children participating in a P1T 
particularly felt burdened by research-only procedures that otherwise wouldn’t be 
needed. In this dissertation, the burdens associated with participation in an early phase 
clinical trial were preliminarily quantified at one site in terms of out of pocket costs, 
needle punctures, time spent at medical appointments, and time lost at other activities. 
However, it was difficult to interpret that data given that comparative information was 
not available for children with high-risk cancer not participating in an early phase clinical 
trial. 
The third key finding was that communication issues between the child and 
parent and between parent / child and health-care providers impacted P1T decision-
making. Preliminary evidence in this dissertation indicates that parents may not be 
aware of the difficulty their children, including older children, had in communicating 
concerns related to their cancer. In addition, double-protection (i.e. the desire to 
protect each other from distress) was found in this dissertation, and may in particular 
hinder open communication between parents and their child.128 Double-protection 
raised concerns that a child’s assent to participate in a P1T was based on a desire to 
ease their parents’ suffering or to acquiesce to their parents’ wishes, rather than on 
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their own preferences.129 Parent and child communication with their providers was 
particularly important during P1T decision-making because parents simultaneously 
struggled to understand the intricacies of P1Ts while dealing with the reality of their 
child’s persistent or advancing cancer. The child’s presence during these difficult 
discussions facilitated their full participation in decision-making; however, it also 
impeded open communication regarding the child’s condition. Study findings indicated 
that the decision to participate in a P1T is influenced by the relationship and trust the 
family has in the oncologist, in that it was more difficult for parents to express hesitancy 
or decline participation in an offered P1T when there was a pre-existing relationship 
with the oncologist.  
The fourth finding was that parents struggled during the on-study process to 
understand the clinical trial system and identify P1Ts for their child. This finding 
highlighted gaps in the education provided to potential participants, and supported 
empiric research which identified challenges educating potential participants about 
pediatric oncology clinical trials and lapses in pediatric oncology P1T consent 
processes.27,132,133,165,166 In particular, parents specified that the primary website for 
finding P1Ts anywhere in the United States, Clinicaltrials.gov160, was confusing to search. 
Parents would also like a tool that would lay out the clinical trial system for them as 
simply as possible.  
The final key finding was that while the dissertation study conducted concurrent 
with P1T participation was feasible, there were specific challenges related to participant 
recruitment and attrition. No instances of undue participant distress or negative 
feedback from participants occurred during either study. However, when a child with a 
poor prognosis had disease progression during the P1T, there was decreased retention 
of participants and completion of study procedures at later time points. An important 
implication for future research with this population is to ensure that data are captured 
at multiple time points, starting before the end of the first course of therapy in the P1T, 
to ensure that attrition does not prohibit capturing the experiences of participants who 
are unable to remain in the P1T. In addition, recruitment challenges existed due to the 
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limited number of pediatric oncology P1T participants at each P1T center. These 
recruitment and retention challenges necessitate that future research with this 
population be conducted at multiple sites.  
5.3 STRENGTHS AND INNOVATION 
This dissertation is innovative in several ways. It was the first synthesis of 
existing evidence on the impact of participation in a pediatric oncology P1T on 
participants’ well-being. Beyond the process of consent, minimal empirical evidence was 
found in the integrative review regarding the experiences or well-being of children with 
cancer or their families while participating in a P1T. As a result, both the pilot and 
phenomenological studies conducted in this dissertation were the first to directly 
elucidate the experiences of children and parents during their participation in a 
pediatric oncology P1T.  
5.4 LIMITATIONS 
Findings of this dissertation should be considered with respect to the following 
limitations. The first study was a longitudinal, pilot study with a small sample, conducted 
at a single site. As a result, a full statistical analysis of results was not possible. Although 
the second study accrued a sufficient sample to achieve thematic redundancy, the 
accrued sample lacked racial, ethnic, and social diversity. In addition, lower-than-
anticipated response rates to recruitment attempts at the medical centers created 
concerns for self-selection bias by those who chose to participate in the second study. 
5.5 IMPLICATIONS FOR PEDIATRIC ONCOLOGY PHASE I CLINICAL TRIALS 
The findings of this dissertation are relevant to the design and management of 
phase I clinical trials by providing insights to improve consent processes. 
Communication during pediatric oncology P1T consent conversations is often 
inadvertently falsely reassuring.133 This dissertation provides evidence of the impact of 
P1T participation on child and parent QOL and well-being that can help to inform 
potential participants during consent discussions.81,133 In addition, by identifying 
challenges parents had understanding the clinical trial system and finding P1Ts for their 
child, this dissertation highlights gaps in education provided to potential participants 
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during recruitment and consent processes.  
Although the prevalence of P1T participants who have profoundly negative 
experiences during the trial is likely very low, P1T researchers should remain aware that 
some participants are unduly burdened by P1T participation. Hesitancies expressed by 
potential participants during consent and enrollment processes should be investigated 
before proceeding with P1T enrollment. Participant concerns expressed during the trial 
should be fully explored to ensure alignment is maintained between participants and 
health care providers throughout the P1T. In addition, providing palliative care services 
simultaneously with P1T participation could help to enhance children’s QOL during the 
P1T.  
The findings of this dissertation indicate that participants may feel particularly 
burdened by research-only lab draws and procedures required as part of the P1T. 
Incentives are provided to participants to acknowledge the burdens of P1Ts, however 
greater care should be taken in the distribution of incentives. By ensuring that 
incentives are provided at the point when the most burdensome procedures are 
completed, and by thoughtfully expressing the importance of the procedures and the 
gratitude of the study team with the disbursement, participants may more definitively 
feel that their sacrifices are appreciated. 
5.6 RECOMMENDATIONS FOR FUTURE RESEARCH 
Two recommendations for future research on P1T participation are proposed. First, 
it is important to prospectively capture the experiences of both children and parents as 
they undertake participation in a P1T. To date, no attempt has been made to 
understand the experiences of children with cancer who participate in pediatric 
oncology P1Ts. Due to the shortened life expectancy of children enrolled in P1Ts, 
obtaining the child’s perspective necessitates a prospective study. In addition, a 
limitation of the phenomenological study was reliance on parents’ retrospective 
reflections of their previous experiences during their child’s P1T participation. A 
prospective study of parents’ experiences will allow direct examination of their 
experiences and will highlight how parents’ perceptions of their experiences alters over 
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time. Quantitative QOL measures used in this dissertation were feasible and provided 
some insights into the experiences of pediatric oncology P1T participants. However, 
research with adult P1T participants identified that participants’ ratings on quantitative 
QOL measures differed substantively from what these same participants reported 
during qualitative interviews.6,111 Thus, it is recommended that this future prospective 
research use mixed methods.  
Second, research needs to be conducted on how to better prepare potential 
participants for P1T participation. Johnson’s self-regulation theory of coping with 
stressful experiences highlights how knowledge and preparation prior to threatening 
health care events increases cooperation and decreases anxiety.167 A pediatric oncology 
P1T educational tool needs to be developed and prospectively tested as part of an 
intervention to improve P1T recruitment and consent processes, and to better prepare 
future P1T participants. This educational tool should be designed collaboratively, using 
community-based participatory research methods, with past P1T participants. It could 
be based on the tool initially designed by Johnson et al.165 The latter tool is a one-page 
generic cover sheet for P1T consent forms that provides the purpose, risks and benefits, 
and voluntary nature of P1Ts, as well as definitions of common P1T terms (i.e. dose 
escalation, dose-limiting toxicity, and maximum tolerated dose), and contact 
information for further support.165  
5.7 CONCLUSIONS 
This dissertation provides insight into the experiences of participation in 
pediatric oncology P1Ts. Findings contributed to the understanding of the impact of P1T 
participation on participants’ well-being and were reassuring that overall parents did 
not regret their child’s participation in a P1T. Further research is needed into children’s 
experiences during P1Ts and to address challenges identified by parents. Understanding 
the impact of P1T participation on participants’ well-being allows clinicians and P1T 
researchers to incorporate participants’ views into P1T management, enhance the 
preparedness of future participants, and minimize any inadvertently negative impact on 
participants’ well-being.5  
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